


Pyrrole Derivatives Used As Modulators of Alpha7 NACHR

Field of the Invention:

The present invention is related to novel compounds of the general formula I,



5

their tautomeric forms, their stereoisomers, their isotopes, their pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as nicotinic acetylcholine receptor $\alpha 7$ subunit ($\alpha 7$ nAChR) modulator.

10

Background of the invention:

Cholinergic neurotransmission, mediated primarily through the neurotransmitter acetylcholine (ACh), is a predominant regulator of the physiological functions of the body via the central and autonomic nervous system. ACh acts on the synapses of the neurons present in all the autonomic ganglia, neuromuscular junctions and the central nervous system. Two distinct classes of ACh target receptors viz. muscarinic (mAChRs) and the nicotinic (nAChRs) have been identified in brain, forming a significant component of receptors carrying its mnemonic and other vital physiological functions.

15

Neural nicotinic ACh receptors (NNRs) belong to the class of ligand-gated ion channels (LGIC) comprising of five subunits ($\alpha 2$ - $\alpha 10$, $\beta 2$ - $\beta 4$) arranged in heteropentameric ($\alpha 4\beta 2$) or homopentameric ($\alpha 7$) configuration (Paterson D et al.,

20

predominant subtypes expressed in the mammalian brain. $\alpha 7$ nAChR has attained prominence as a therapeutic target due to its abundant expression in the learning and memory centers of brain, hippocampus and the cerebral cortex (Rubboli F et al., *Neurochem. Int.*, 1994, 25, 69-71). Particularly, $\alpha 7$ nAChR is characterized by a high Ca^{2+} ion permeability, which is responsible for neurotransmitter release and consequent modulation of excitatory and inhibitory neurotransmission (Alkondon M et al., *Eur. J. Pharmacol.*, 2000, 393, 59-67; Dajas-Bailador F et al., *Trends Pharmacol. Sci.*, 2004, 25, 317-324). Furthermore, high Ca^{2+} ion influx also has implications on the long-term potentiation of memory via alterations in gene expression (Bitner RS et al., *J. Neurosci.*, 2007, 27, 10578-10587; McKay BE et al., *Biochem. Pharmacol.*, 2007, 74, 1120-1133).

Several recent studies have confirmed the role of $\alpha 7$ nAChR in neural processes like attention, memory and cognition (Mansvelder HD et al., *Psychopharmacology (Berl)*, 2006, 184, 292-305; Chan WK et al., *Neuropharmacology*, 2007, 52, 1641-1649; Young JW et al., *Eur. Neuropsychopharmacol.*, 2007, 17, 145-155). Gene polymorphisms associated with the $\alpha 7$ nAChR protein CHRNA7 have been implicated in the genetic transmission of schizophrenia, related neurophysiological sensory gating deficits and resultant cognitive impairment (Freedman R et al., *Biol. Psychiatry*, 1995, 38, 22-33; Tsuang DW et al., *Am. J. Med. Genet.*, 2001, 105, 662-668). Also, preclinical studies in $\alpha 7$ nAChR knock-out and anti-sense oligonucleotide treated mice have demonstrated impaired attention and defective cognition underscoring the prominent role of $\alpha 7$ nAChR in cognition (Curzon P et al., *Neurosci. Lett.*, 2006, 410, 15-19; Young JW et al., *Neuropsychopharmacology*, 2004, 29, 891-900). Additionally, pharmacological blockade of $\alpha 7$ nAChR impairs memory and its activation enhances same in preclinical rodent models implicating $\alpha 7$ nAChR as target for cognitive enhancement (Hashimoto K et al., *Biol. Psychiatry*, 2008, 63, 92-97).

Pathological brain function in sensory-deficit disorders has been associated with nicotinic cholinergic transmission particularly through $\alpha 7$ receptors (Freedman R et al., *Biol. Psychiatry*, 1995, 38, 22-33; Tsuang DW et al., *Am. J. Med. Genet.*,

2001, 105, 662-668; Carson R et al., Neuromolecular, 2008, Med 10, 377-384; Leonard S et al., Pharmacol. Biochem. Behav., 2001, 70, 561-570; Freedman R et al., Curr. Psychiatry Rep., 2003, 5, 155-161; Cannon TD et al., Curr. Opin. Psychiatry, 2005, 18, 135-140). A defective pre-attention processing of sensory information is understood to be the basis of cognitive fragmentation in schizophrenia and related neuropsychiatric disorders (Leiser SC et al., Pharmacol. Ther., 2009, 122, 302-311). Genetic linkage studies have traced sharing of the $\alpha 7$ gene locus for several affective, attention, anxiety and psychotic disorders (Leonard S et al., Pharmacol. Biochem. Behav., 2001, 70, 561-570; Suemaru K et al., Nippon. Yakurigaku. Zasshi., 2002, 119, 295-300). Modulation of the nicotinic cholinergic receptors, particularly $\alpha 7$ may provide for efficacy in a range of cognitive states, right from pre-attention to attention and subsequently working, reference and recognition memory. Accordingly, this invention may find application in the treatment and prophylaxis of multitude of disease conditions including, either one or combinations of, schizophrenia, schizophreniform disorder, cognitive deficits in schizophrenia, brief psychotic disorder, delusional disorder, schizoaffective disorder, shared psychotic disorder, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, attention deficit disorder, attention deficit hyperactivity disorder (ADHD), depression, manic depression, major depressive disorder, posttraumatic stress disorder, generalized anxiety disorder, tourette's syndrome, cyclothymic disorder, dysthymic disorder, agoraphobia, panic disorder (with or without agoraphobia), phobias (including social phobia) and bipolar disorders (Thomsen MS et al., Curr. Pharm. Des. 2010, 16, 323-343; Peng ZZ et al., Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008, 25, 154-158; Young JW et al., Eur. Neuropsychopharmacol. 2007, 17, 145-155; Martin LF et al., Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B, 611-614; Martin LF et al., Psychopharmacology (Berl), 2004, 174, 54-64; Feher A et al., Dement. Geriatr. Cogn. Disord. 2009, 28, 56-62; Wilens TE et al., Biochem. Pharmacol. 2007, 74, 1212-1223; Verbois SL et al., Neuropharmacology, 2003, 44, 224-233; Sanberg PR et al., Pharmacol. Ther. 1997, 74, 21-25). Cholinergic system, particularly through $\alpha 7$ nAChR seems to have implications in traumatic brain

injury-induced psychosis. Chronic nicotine treatment has shown to attenuate same. Thus, this invention may also find application in the treatment of deficits in cholinergic $\alpha 7$ nAChR following traumatic brain injury (Bennouna M et al., *Encephale*, 2007, 33, 616-620; Verbois SL et al., *Neuropharmacology*, 2003, 44, 224-233).

Perturbations in the cholinergic and glutamatergic homeostasis, has long been implicated as causative factors for host of neurological disease, including dementia(s) (Nizri E et al., *Drug News Perspect.* 2007, 20, 421-429). Dementia is a severe, progressive, multi-factorial cognitive disorder affecting memory, attention, language and problem solving. Nicotinic ACh receptor, particularly the interaction of $\alpha 7$ receptor to $A\beta_{1-42}$ is implicated as an up-stream pathogenic event in Alzheimer's disease, a major causative factor for dementia (Wang HY et al., *J. Neurosci.*, 2009, 29, 10961-10973). Moreover, gene polymorphisms in CHRNA7 have been implicated in dementia with Lewy bodies (DLB) and Pick's disease (Feher A et al., *Dement. Geriatr. Cogn. Disord.* 2009, 28, 56-62). Modulation of nicotinic ACh receptors, particularly the $\alpha 7$ subtype could help supplement the down-regulated cholinergic receptor expression and transmission as in dementia(s), and also slowing disease progression by reduction of $\alpha 7$ - $A\beta_{1-42}$ complexation and internalization in AD and Down's syndrome (Nordberg A et al., *Neurotox. Res.* 2000, 2, 157-165; Haydar SN et al., *Bioorg. Med. Chem.*, 2009, 17, 5247-5258; Deutsch SI et al., *Clin. Neuropharmacol.*, 2003, 26, 277-283). Appropriately, this invention may find application in the treatment and prophylaxis of multitude of disease conditions including, either one or combinations of, dementia(s) due to Alzheimer's disease, dementia with Lewy bodies, Down's syndrome, head trauma, Stroke, hypoperfusion, Parkinson's disease, Huntington's disease, Prion diseases, progressive supranuclear palsy, radiation therapy, brain tumors, normal-pressure hydrocephalus, subdural hematoma, human immunodeficiency virus (HIV) infection, vitamin deficiency, hypothyroidism, drugs, alcohol, lead, mercury, aluminium, heavy metals, syphilis, Lyme disease, viral encephalitis, fungal infection and cryptococcosis (Zhao X et al., *Ann N Y Acad. Sci.*, 2001, 939, 179-

186; Perry E et al., *Eur. J. Pharmacol.*, 2000, 393, 215-222; Harrington CR et al., *Dementia*, 1994, 5, 215-228; Wang J et al., *J. Neurosci. Res.*, 2010, 88, 807-815).

Disease modification potential of nAChRs particularly the $\alpha 7$ receptor has application for disease-modification of Alzheimer's disease (AD) and Parkinson's disease (PD) by enhancing neuron survival and preventing neurodegeneration (Wang et al. 2009; Nagele RG et al., *Neuroscience*, 2002, 110, 199-211; Jeyarasasingam G et al., *Neuroscience*, 2002, 109, 275-285). Additionally, $\alpha 7$ nAChR induced activation of anti-apoptotic (BCL-2) and anti-inflammatory pathways in brain could have neuroprotective effects in neurodegenerative diseases (Marrero MB et al., *Brain Res.*, 2009, 1256, 1-7). Thus, this invention may find application in the prophylaxis and preventive measures immediately after early-stage identification of neurodegenerative disease like Alzheimer's disease and Parkinson's disease.

Dopamine containing neurons of ventral tegmental area (VTA) and laterodorsal tegmental nucleus (LDT) are known to express nicotinic ACh receptors, particularly $\alpha 4$, $\alpha 3$, $\beta 2$, $\beta 3$, $\beta 4$ subunits (Kuzmin A et al., *Psychopharmacology (Berl)*, 2009, 203, 99-108). Nicotinic ACh receptors, $\alpha 4\beta 2$ and $\alpha 3\beta 4$ have been identified with candidate-gene approach to have strong mechanistic link for nicotine addiction (Weiss RB et al., *PLoS Genet* 2008, 4, e1000125). $\alpha 7$ nAChR has particularly been studied for a putative role in cannabis addiction (Solinas M et al., *J. Neurosci.*, 2007, 27, 5615-5620). Varenicline, a partial agonist at $\alpha 4\beta 2$, has demonstrated better efficacy in reducing the smoking addiction and relapse prevention in comparison to bupropion (Ebbert JO et al., *Patient Prefer Adherence*, 2010, 4, 355-362). Modulation of nicotinic ACh receptors particularly $\alpha 4\beta 2$, $\alpha 3\beta 4$ and $\alpha 7$ may have implications in the development of therapies for nicotine, cannabis addiction and relapse prevention. Accordingly, this invention may find application in the prophylaxis or therapy of nicotine addiction, cannabis addiction, relapse prevention of nicotine or cannabis addiction. Additionally, this invention may also provide for an alternative therapy for non-responding addiction patients, patients having intolerable side-effects with de-addiction therapies or those requiring long-

term maintenance therapies.

Presence of a high-affinity nicotine binding site at $\alpha 4\beta 2$ nAChR, in the descending inhibitory pathways from brainstem has sparked interest in the antinociceptive properties of nicotinic ACh receptor agonists like epibatidine (Decker MW et al., Expert. Opin. Investig. Drugs, 2001, 10, 1819-1830). Several new developments have opened the area for use of nicotinic modulators for therapy of pain (Rowbotham MC et al., Pain., 2009, 146, 245-252). Appropriate modulation of the nicotinic ACh receptors could provide for remedial approach to pain related states. Thus, this invention may find application in the treatment and prophylaxis of multitude of pain conditions including, either one or combinations of, pain arising from, peripheral nervous system (PNS), post-diabetic neuralgia (PDN), post-herpetic neuralgia (PHN), multiple sclerosis, Parkinson's disease, low-back pain, fibromyalgia, post-operative pain, acute pain, chronic pain, mononeuropathy, primary lateral sclerosis, pseudobulbar palsy, progressive muscular palsy, progressive bulbar palsy, postpolio syndrome, diabetes induced polyneuropathy, acute demyelinating polyneuropathy (Guillain-Barre syndrome), acute spinal muscular atrophy (Werdnig-Hoffman disease) and secondary neurodegeneration (Donnelly-Roberts DL et al., J. Pharmacol. Exp. Ther., 1998, 285, 777-786; Rowley TJ et al., Br. J. Anaesth., 2010, 105, 201-207; Bruchfeld A et al., J. Intern. Med., 2010, 268, 94-101).

Another key role of the $\alpha 7$ nAChR is the ability to modulate the production of pro-inflammatory cytokines, like interleukins (IL), tumor necrosis factor alpha (TNF- α), and high mobility group box (HMGB-1) in the central nervous system. Consequently, an anti-inflammatory and antinociceptive effect in pain disorders have been demonstrated (Damaj MI et al., Neuropharmacology, 2000, 39, 2785-2791). Additionally, 'cholinergic anti-inflammatory pathway' is proposed to be a regulatory of local and systemic inflammation and neuro-immune interactions through neural and humoral pathways (Gallowitsch-Puerta M et al., Life Sci. 2007, 80, 2325-2329; Gallowitsch-Puerta and Pavlov 2007; Rosas-Ballina M et al., Mol. Med. 2009, 15, 195-202; Rosas-Ballina M et al., J. Intern. Med. 2009, 265, 663-679). Selective modulators of nicotinic ACh receptors, particularly $\alpha 7$ type, like

GTS-21, attenuate cytokine production and IL-1 β after endotoxin exposure. Furthermore, $\alpha 7$ nAChR are understood to have a central role in arthritis pathogenesis and potential therapeutic strategy for treatment of joint inflammation (Westman M et al., Scand J. Immunol. 2009, 70, 136-140). A putative role for $\alpha 7$ nAChR has also been implicated in severe sepsis, endotoxemic shock and systemic inflammation (Jin Y et al. (2010) Int. J. Immunogenet. Liu C et al., Crit. Care Med. 2009, 37, 634-641). This invention may thus find application in the treatment and prophylaxis of plethora of inflammation and pain related states involving TNF- α and thus providing symptomatic relief in either any one or combination of, rheumatoid arthritis, bone resorption diseases, atherosclerosis, inflammatory bowel disease, Crohn's disease, inflammation, cancer pain, muscle degeneration, osteoarthritis, osteoporosis, ulcerative colitis, rhinitis, pancreatitis, spondylitis, acute respiratory distress syndrome (ARDS), joint inflammation, anaphylaxis, ischemia reperfusion injury, multiple sclerosis, cerebral malaria, septic shock, tissue rejection of graft, brain trauma, toxic shock syndrome, herpes virus infection (HSV-1 & HSV-2), herpes zoster infection, sepsis, fever, myalgias, asthma, uveitis, contact dermatitis, obesity-related disease and endotoxemia (Giebelen IA T et al., Shock, 2007, 27, 443-447; Pena G et al., Eur. J. Immunol., 2010, 40, 2580-2589).

Angiogenesis, is a critical physiological process for the cell survival and pathologically important for cancer proliferation; several non-neural nicotinic ACh receptors, particularly $\alpha 7$, $\alpha 5$, $\alpha 3$, $\beta 2$, $\beta 4$, are involved (Arias HR et al., Int. J. Biochem. Cell Biol., 2009, 41, 1441-1451; Heeschen C et al., J. Clin. Invest., 2002, 110, 527-536). A role of nicotinic ACh receptors in the development of cervical cancer, lung carcinogenesis and paediatric lung disorders in smoking-exposed population has also been studied (Calleja-Macias IE et al., Int. J. Cancer, 2009, 124, 1090-1096; Schuller HM et al., Eur. J. Pharmacol., 2000, 393, 265-277). It is thus, imperative for the modulators of nicotinic ACh receptors, to have a modulatory role in angiogenesis and cancer cell survival. Thus, this invention may find application in the treatment and prophylaxis of multitude of cancerous conditions including, one or combination of, acute or chronic myelogenous

leukemia, multiple myeloma, tumor growth inhibition, angiogenesis and cancer associated-cachexia.

Several $\alpha 7$ nAChR agonists, partial agonists, have been characterized for their efficacy in clinical and preclinical studies. EVP-6124, an agonist at $\alpha 7$ nAChR, has demonstrated significant improvement in sensory processing and cognition biomarkers in Phase Ib study with patients suffering from schizophrenia (EnVivo Pharmaceuticals press release 2009, Jan 12). GTS-21 (DMXB-Anabaseine), an $\alpha 7$ nAChR agonist, in the P II clinical trials, has shown efficacy in improving cognitive deficits in schizophrenia and inhibition of endotoxin-induced TNF- α release (Olinicy A et al., Biol. Psychiatry, 2005, 57(8, Suppl.), Abst 44; Olinicy A et al., Arch. Gen. Psychiatry, 2006, 63, 630-638; Goldstein R et al., Acad. Emerg. Med., 2007, 14(15, Suppl. 1), Abst. 474). CP-810123, a $\alpha 7$ nAChR agonist, exhibits protection against the scopolamine-induced dementia and inhibition of amphetamine-induced auditory evoked potentials in preclinical studies (O'Donnell CJ et al., J. Med. Chem., 2010, 53, 1222-1237). SSR-180711A, also an $\alpha 7$ nAChR agonist, enhances learning and memory, and protects against MK-801/Scopolamine-induced memory loss and prepulse inhibition in preclinical studies (Redrobe JP et al., Eur. J. Pharmacol., 2009, 602, 58-65; Dunlop J et al., J. Pharmacol. Exp. Ther., 2009, 328, 766-776; Pichat P et al., Neuropsychopharmacology, 2007, 32, 17-34). SEN-12333, protected against scopolamine-induced amnesia in passive avoidance test in preclinical studies (Roncarati R et al., J. Pharmacol. Exp. Ther., 2009, 329, 459-468). AR-R-17779, an agonist at $\alpha 7$ nAChR, exhibits improvement in the social recognition task performed in rats (Van KM et al., Psychopharmacology (Berl), 2004, 172, 375-383). ABBF, an agonist at $\alpha 7$ nAChR, improves social recognition memory and working memory in Morris maze task in rats (Boess FG et al., J. Pharmacol. Exp. Ther., 2007, 321, 716-725). TC-5619, a selective $\alpha 7$ nAChR agonist has demonstrated efficacy in animal models of positive and negative symptoms and cognitive dysfunction in schizophrenia (Hauser TA et al., Biochem. Pharmacol., 2009, 78, 803-812).

An alternative strategy to reinforce or potentiate the endogenous cholinergic neurotransmission of ACh without directly stimulating the target receptor is the positive allosteric modulation (PAM) of $\alpha 7$ nAChR (Albuquerque EX et al., Alzheimer Dis. Assoc. Disord., 2001, 15 Suppl 1, S19-S25). Several PAMs have been characterized, albeit in the preclinical stages of discovery. A-86774, $\alpha 7$ nAChR PAM, improves sensory gating in DBA/2 mice by significantly reducing the T:C ratio in a preclinical model of schizophrenia (Faghieh R et al., J. Med. Chem., 2009, 52, 3377-3384). XY-4083, an $\alpha 7$ nAChR PAM, normalizes the sensorimotor gating deficits in the DBA/2 mice and memory acquisition in 8-arm radial maze without altering the receptor desensitization kinetics (Ng HJ et al., Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 8059-8064). Yet another PAM, PNU-120596, profoundly alters $\alpha 7$ nAChR desensitization kinetics and simultaneously protecting against the disruption of prepulse inhibition by MK-801. NS-1738, another PAM, has exhibited efficacy in-vivo in the animal models of social recognition and spatial memory acquisition in the Morris maze task (Timmermann DB et al., J. Pharmacol. Exp. Ther., 2007, 323, 294-307). In addition, several patents/applications published are listed below - US20060142349, US20070142450, US20090253691, WO2007031440, WO2009115547, WO2009135944, WO2009127678, WO2009127679, WO2009043780, WO2009043784, US7683084, US7741364, WO2009145996, US20100240707, WO2011064288, US20100222398, US20100227869, EP1866314, WO2010130768, WO2011036167, US20100190819 disclose efficacy of allosteric modulators of nicotinic ACh receptors and underscoring their therapeutic potential.

Following are the abbreviations used and meaning thereof in the specification:

- 25 ACh: Acetylcholine.
- AD: Alzheimer 's disease.
- ADC: AIDS dementia complex.
- ADHD: attention deficit hyperactivity disorder.
- AIDS: Acquired immunodeficiency syndrome.
- 30 ARDS: acute respiratory distress syndrome.

- DCC: 1,3-dicyclohexylcarbodiimide.
DCE: dichloroethane.
DCM: dichloromethane.
DLB: dementia with Lewy bodies.
- 5 DMF: N,N-dimethylformamide.
EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
FLIPR: Fluorometric Imaging Plate Reader.
HBSS: Hank's balanced salt solution.
HEPES: 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid.
- 10 HMGB: high mobility group box.
HOAT: 1-hydroxy-7-azabenzotriazole.
HOBT: hydroxybenzotriazole hydrate.
HPLC: High Performance liquid chromatography.
IL: interleukins.
- 15 LDT: laterodorsal tegmental nucleus.
LGIC: ligand-gated ion channels.
MCI: mild cognitive impairment.
NBS: N-bromosuccinamide.
NCS: N-chlorosuccinamide.
- 20 NIS: N-iodosuccinamide
NNRs: Neural nicotinic ACh receptors.
PAM: positive allosteric modulation.
PD: Parkinson's disease.
PDN: post-diabetic neuralgia.
- 25 PHN: post-herpetic neuralgia.
PMBO: p-methoxy benzyloxy.
PNS: peripheral nervous system.
TBI: traumatic brain injury.
THF: Tetrahydrofuran.
- 30 TLC: Thin layer chromatography.
TMS: tetramethylsilane.

TNF- α : tumor necrosis factor alpha.

VTa: ventral tegmental area.

$\alpha 7$ nAChR: nicotinic acetylcholine receptor $\alpha 7$ subunit.

5 **Objective of the Invention:**

The main objective of the present invention is therefore to provide novel compounds of the general formula I, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, process and intermediates for the preparation of the above said compounds
10 which have $\alpha 7$ nAChR modulatory activity.

Summary of the Invention


According to one aspect of the present invention there is provided compounds represented by the general formula I, its tautomeric forms, its stereoisomers its
15 isotopes, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates, its co-crystals, their combinations with suitable medicament and pharmaceutical compositions containing them.

In yet another aspect, the present invention provides a process for the preparation of the compounds of the general formula I.

20 A further aspect of the present invention is to provide novel intermediates, a process for their preparation and their use in methods of making compounds of the general formula I.

Detailed Description of the invention:

The present invention relates to a compound of the general formula I, its
25 tautomeric forms, its stereoisomers, its isotopes, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates, its co-crystals, their combinations with suitable medicament and pharmaceutical compositions containing them.




wherein,

R^1 is selected from hydrogen, halogen, optionally substituted alkyl, perhaloalkyl, optionally substituted cycloalkyl, optionally substituted aryl; optionally substituted
5 heterocyclyl, optionally substituted heteroaryl;

R^2 is selected from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or $-NR^5(R^6)$, $-A^1R^5$, $-N(R^5)OR^6$;

R^3 is selected from hydrogen, optionally substituted alkyl, halo, optionally
10 substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, cyano, nitro or $-NR^5(R^6)$, $-OR^5$;

R^4 is



wherein, phenyl ring 'D' is fused with ring 'E', which is a non-aromatic five to eight
15 member ring inclusive of 'Y' group(s);

Y is independently selected at each repetition from -O-, -S-, -NH-, , or _{l_q},

where q = 1 - 4; wherein when Y is selected as -NH- or _{l_q}, it is optionally substituted by [R⁸]_n;

wherein, R⁵ and R⁶ are independently selected from hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, R^{9a}C(=A¹)-;

R⁷ is selected independently at each occurrence from the group consisting of halogen, optionally substituted alkyl, optionally substituted cycloalkyl;

R⁸ is independently selected at each occurrence from the group consisting of optionally substituted alkyl, R^{9a}A¹-, R^{9a}C(=A¹)-;

m = 0 to 2;

n = 0 to 3;

p = 0 to 4;

wherein, R⁹ wherever it appears, is selected from hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; and A¹ is selected from O and S;

R^{9a} wherever it appears, is selected from optionally substituted C₁₋₆ alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

wherein,

the term "optionally substituted alkyl", means a alkyl group optionally substituted with 1 to 6 substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl, $R^{10a}SO_2-$, $R^{10a}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$,
 5 $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;

the term "optionally substituted heteroalkyl" means a heteroalkyl group optionally substituted with 1 to 6 substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl.

the term "optionally substituted cycloalkyl" means a cycloalkyl group optionally substituted with 1 to 6 substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, hereroaryl, alkyl, $R^{10a}C(=O)-$, $R^{10a}SO_2-$, $R^{10a}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;
 10

the term "optionally substituted aryl" means (i) an aryl group optionally substituted with 1 to 3 substituents selected independently from the group comprising of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, C_3 to C_6 cycloalkyl, C_1 to C_6 perhaloalkyl, alkyl- $O-$, perhaloalkyl- $O-$, alkyl- $N(alkyl)-$, alkyl- $N(H)-$, H_2N- , alkyl- SO_2- , perhaloalkyl- SO_2- , alkyl- $C(=O)N(alkyl)-$, alkyl- $C(=O)N(H)-$, alkyl- $N(alkyl)C(=O)-$,
 20 alkyl- $N(H)C(=O)-$, $H_2NC(=O)-$, alkyl- $N(alkyl)SO_2-$, alkyl- $N(H)SO_2-$, H_2NSO_2- , 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl- $C(=O)-$, (ii) an aryl ring optionally fused with cycloalkane or heterocycle across a bond optionally substituted with oxo, alkyl or alkyl- $C(=O)-$;

the term "optionally substituted heterocyclyl" means a (i) heterocyclyl group optionally substituted on ring carbons with 1 to 6 substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, hereroaryl, alkyl, $R^{10a}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$,
 25

(R¹⁰)(alkyl)NC(=A¹)N(H)-; (ii) heterocyclyl group optionally substituted on ring nitrogen(s) with substituents selected from the group comprising of aryl, heteroaryl, alkyl, R^{10a}C(=O)-, R^{10a}SO₂-, R^{10a}OC(=O)-, (R¹⁰)(H)NC(=O)-, (R¹⁰)(alkyl)NC(=O)-;

- 5 the term "optionally substituted heteroaryl" means a heteroaryl group optionally substituted with 1 to 3 substituents selected independently from the group comprising of halogen, nitro, cyano, hydroxy, C₁ to C₆ alkyl, C₃ to C₆ cycloalkyl, C₁ to C₆ perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H₂N-, alkyl-SO₂-, perhaloalkyl-SO₂-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-
 10 N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H₂NC(=O)-, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H₂NSO₂-, 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-;

wherein R¹⁰ is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and A¹ is selected from S and O; and R^{10a} is selected from alkyl,
 15 perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.


Other aspect of the invention of the present invention is compound of formula I as described hereinabove wherein when p is selected as 0 then n is selected from the integers ranging between 1 and 4.

Preferred embodiment of the present invention is compound of formula I as defined
 20 herein above, wherein R¹ is selected from methyl.


Other preferred embodiment of the present invention is compound of formula I as defined hereinabove, wherein, R² is selected from ethyl and ethoxy.

Another preferred embodiment of the present invention is compound of formula I as defined hereinabove, wherein, R³ is selected from hydrogen and methyl.

25 Yet another preferred embodiment of the present invention is compound of formula I as defined hereinabove, wherein, R⁴ is selected from following groups:



Further preferred embodiment of the present invention is compound of formula I as defined hereinabove, wherein R^1 is selected from methyl; R^2 is selected from ethyl and ethoxy; R^3 is selected from hydrogen and methyl; and R^4 is selected from following groups:



- 5 General terms used in formula can be defined as follows; however, the meaning stated hereinbelow should not be interpreted as limiting the scope of the term *per se*.

The term "**alkyl**", as used herein, means a straight or branched chain hydrocarbon containing from 1 to 20 carbon atoms. The term as defined herein also includes
 10 unsaturated chains containing 2 to 20 carbon atoms and one or more unsaturations (double or triple bonds) as in alkenyl and alkynyl groups. Preferably the alkyl chain may contain 1 to 10 carbon atoms, and alkenyl and alkynyl chains may contain 2 to 10 carbons. More preferably alkyl chain may contain up to 6 carbon atoms. Representative examples of alkyl include, but are not limited to,
 15 methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, allyl, vinyl, acetylene, and n-hexyl.

Alkyl as defined hereinabove may be optionally substituted with one or more substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, heteroaryl, cycloalkyl, $R^{10a}SO_2-$, $R^{10a}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$; wherein R^{10} is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and A^1 is selected from S and O; and R^{10a} is selected from alkyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.

The term **“perhaloalkyl”** used herein means an alkyl group as defined hereinabove wherein all the hydrogen atoms of the said alkyl group are substituted with halogen. The perhaloalkyl group is exemplified by trifluoromethyl, pentafluoroethyl and the like.

The term **“heteroalkyl”** as used herein means an ‘alkyl’ group wherein one or more of the carbon atoms replaced by $-O-$, $-S-$, $-S(O_2)-$, $-S(O)-$, $-N(R^m)-$, $Si(R^m)R^n-$ wherein, R^m and R^n are independently selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl.

The term **“cycloalkyl”** as used herein, means a monocyclic, bicyclic, or tricyclic non-aromatic ring system containing from 3 to 14 carbon atoms, preferably monocyclic cycloalkyl ring containing 3 to 6 carbon atoms. The ring may contain one or more unsaturations (double or triple bonds). Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Bicyclic ring systems are also exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane, bicyclo[3.3.2]decane, bicyclo[3.1.0]hexane, bicyclo[4.1.0]heptane, bicyclo[3.2.0]heptanes, octahydro-1H-indene. Tricyclic ring systems are also exemplified by a bicyclic ring system in which two non-adjacent

carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0^{3,7}]nonane and tricyclo[3.3.1.1^{3,7}]decane (adamantane). The term cycloalkyl also include spiro systems wherein one of the ring is annulated on a single carbon atom such ring systems are exemplified by spiro[2.5]octane, spiro[4.5]decane, spiro[bicyclo[4.1.0]heptane-2,1'-cyclopentane], hexahydro-2'H-spiro[cyclopropane-1,1'-pentalene].

cycloalkyl as defined hereinabove may be optionally substituted with one or more substituents selected independently from the group comprising of oxo, halogen, nitro, cyano, aryl, heteroaryl, alkyl, R^{10a}C(=O)-, R^{10a}SO₂-, R^{10a}A¹-, R^{10a}OC(=O)-, R^{10a}C(=O)O-, (R¹⁰)(H)NC(=O)-, (R¹⁰)(alkyl)NC(=O)-, R^{10a}C(=O)N(H)-, (R¹⁰)(H)N-, (R¹⁰)(alkyl)N-, (R¹⁰)(H)NC(=A¹)N(H)-, (R¹⁰)(alkyl)NC(=A¹)N(H)-; wherein R¹⁰ is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and A¹ is selected from S and O; and R^{10a} is selected from alkyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.

The term "**aryl**" refers to a monovalent monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring system. Examples of aryl groups include but not limited to phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like. The said aryl group also includes aryl rings fused with heteroaryl or heterocyclic rings such as 2,3-dihydro-benzo[1,4]dioxin-6-yl; 2,3-dihydro-benzo[1,4]dioxin-5-yl; 2,3-dihydro-benzofuran-5-yl; 2,3-dihydro-benzofuran-4-yl; 2,3-dihydro-benzofuran-6-yl; 2,3-dihydro-benzofuran-6-yl; 2,3-dihydro-1H-indol-5-yl; 2,3-dihydro-1H-indol-4-yl; 2,3-dihydro-1H-indol-6-yl; 2,3-dihydro-1H-indol-7-yl; benzo[1,3]dioxol-4-yl; benzo[1,3]dioxol-5-yl; 1,2,3,4-tetrahydroquinolinyl; 1,2,3,4-tetrahydroisoquinolinyl; 2,3-dihydrobenzothien-4-yl, 2-oxoindolin-5-yl.

Aryl as defined hereinabove may be optionally substituted with one or more substituents selected independently from the group comprising of halogen, nitro, cyano, hydroxy, C₁ to C₆ alkyl, C₃ to C₆ cycloalkyl, C₁ to C₆ perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H₂N-, alkyl-SO₂-, perhaloalkyl-SO₂-,

alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, H₂NC(=O)-, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H₂NSO₂-, 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-.

- 5 The term "**heteroaryl**" refers to a 5-14 membered monocyclic, bicyclic, or tricyclic ring system having 1-4 ring heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated), wherein at least one ring in the ring system is aromatic. Heteroaryl groups may be optionally substituted with one or more substituents. In
- 10 one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include but not limited to pyridyl, 1-oxo-pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, benzoxazolyl,
- 15 benzofuranyl, indoliziny, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, and benzo(b)thienyl, 2,3-thiadiazolyl, 1H-pyrazolo[5,1-c]-1,2,4-triazolyl, pyrrolo[3,4-d]-1,2,3-triazolyl, cyclopentatriazolyl, 3H-pyrrolo[3,4-c] isoxazolyl and the like.
- 20 heteroaryl as defined hereinabove may be optionally substituted with one or more substituents selected independently from the group comprising of halogen, nitro, cyano, hydroxy, C₁ to C₆ alkyl, C₃ to C₆ cycloalkyl, C₁ to C₆ perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H₂N-, alkyl-SO₂-, perhaloalkyl-SO₂-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-,
- 25 H₂NC(=O)-, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H₂NSO₂-, 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-.

The term "**heterocycle**" or "heterocyclic" as used herein, means a 'cycloalkyl' group wherein one or more of the carbon atoms replaced by -O-, -S-, -S(O₂)-, -S(O)-, -

N(R^m)-, -Si(R^m)Rⁿ-, wherein, R^m and Rⁿ are independently selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclyl. The heterocycle may be connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heterocycle. Representative examples of
 5 monocyclic heterocycle include, but are not limited to, azetidiny, azepanyl, aziridiny, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidiny, isothiazoliny, isothiazolidiny, isoxazoliny, isoxazolidiny, morpholiny, oxadiazoliny, oxadiazolidiny, oxazoliny, oxazolidiny, piperaziny, piperidiny, pyranyl, pyrazoliny, pyrazolidiny, pyrroliny, pyrrolidiny,
 10 tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny, thiadiazolidiny, thiazoliny, thiazolidiny, thiomorpholiny, 1.1-dioxidothiomorpholiny (thiomorpholine sulfone), thiopyranyl, and trithianyl. Representative examples of bicyclic heterocycle include, but are not limited to 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-1-benzofuranyl, 2,3-dihydro-1-benzothieryl, 2,3-dihydro-1 H-indolyl and 1,2,3,4-tetrahydroquinoliny. The term heterocycle also
 15 include bridged heterocyclic systems such as azabicyclo[3.2.1]octane, azabicyclo[3.3.1]nonane and the like.

Heterocyclyl group may optionally be substituted on ring carbons with one or more substituents selected independently from the group comprising of oxo, halogen,
 20 nitro, cyano, aryl, heteroaryl, alkyl, R¹⁰A¹-, R^{10a}OC(=O)-, R^{10a}C(=O)O-, (R¹⁰)(H)NC(=O)-, (R¹⁰)(alkyl)NC(O)-, R^{10a}C(=O)N(H)-, (R¹⁰)(H)N-, (R¹⁰)(alkyl)N-, (R¹⁰)(H)NC(=A¹)N(H)-, (R¹⁰)(alkyl)NC(=A¹)N(H)-; wherein R¹⁰ is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and A¹ is selected from S and O; and R^{10a} is selected from alkyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or
 25 heterocyclyl.

Heterocyclyl group may further optionally be substituted on ring nitrogen(s) with substituents selected from the group comprising of aryl, heteroaryl, alkyl, R^{10a}C(=O)-, R^{10a}SO₂-, R^{10a}OC(=O)-, (R¹⁰)(H)NC(=O)-, (R¹⁰)(alkyl)NC(=O)-; wherein R¹⁰ is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and
 30 R^{10a} is selected from alkyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.

A compound its stereoisomers, racemates, pharmaceutically acceptable salt and pharmaceutical composition thereof as described hereinabove wherein the compound of general formula I is selected from:

- 5 1. 4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
2. 4-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
- 10 3. 4-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5-dimethyl-4-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
4. Ethyl 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,4-dimethyl-1-(4-sulfamoylphenyl)-1*H*-pyrrole-3-carboxylate
- 15 5. 4-(5-(2,3-dihydro-1*H*-inden-4-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
6. 4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
- 20 7. 4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
8. 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
- 25 9. 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.
- 30 10. 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.

11. 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

5 12. 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

13. 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

10 14. 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

15 15. 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

16. 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

20 17. 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.


18. 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

25 19. 4-(2-methyl-3-propionyl-5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

30 20. 4-(2-methyl-3-propionyl-5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

According to another aspect of the present invention, the compounds of general formula I where all the symbols are as defined earlier were prepared by method described below in scheme 1. However, the invention may not be limited to these

methods; the compounds may also be prepared by using procedures described for structurally related compounds in the literature.



Compound of the formula I can be prepared starting from compounds represented
 5 by general formulae II and III by subjecting them to Friedel-Crafts reaction in the
 presence of Lewis acid as described in the literature EP 2168959 to give the

Compounds of formula IV. Friedal Craft reaction can be carried out under different conditions well known in the art.

Alternatively, compound of formula IV can be prepared according to the appropriate procedure given in literature such as US 6313107, US5037825 and
5 Journal of Med. Chemistry, 2006, 49,478 or the like.

Compound of the formula IV where symbols R^4 is same as defined earlier in general formula and R^3 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, $-OR^6$ where R^6 is not selected as hydrogen
10 undergo for halogenation to provide the compounds of formula V. Halogenation can be carried out under a condition adopting procedure generally used in the synthetic organic chemistry using bromine, iodine, N-halosuccinamide, sufuryl chloride, cupric chloride, cupric bromide or cupric iodide preferably bromine and cupric chloride using a solvent such as ethyl acetate, dichloromethane, methanol,
15 THF, 1,4-dioxane and the like. Preferably dichloromethane or methanol are used.

Alternatively, Compounds of formula V can be prepared starting from compounds represented by general formulae II by reacting it with compound VI under Friedal-Crafts condition in the presence of Lewis acid such as $AlCl_3$ and the like as described in the literature EP 2168959 to give the compound of formula V. Friedal
20 Craft reaction can be carried out under different conditions well known in the art.

Compound of formula V where symbols R^3 and R^4 are same as defined for compound IV, and X^1 is halogen when treated with base such as potassium carbonate, sodium hydride, preferably pulverized sodium under room temperature to heated conditions in a solvent such as THF, an aromatic hydrocarbon such as
25 benzene, toluene and the like. Preferably toluene and compound of the formula VII where R^1 is optionally substituted alkyl, perhaloalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, provide diketo ester compound VIII.

Compound of the formula VII can be prepared according to the procedure given in literature such as Chem. Pharm. Bull. 1982, 30, 2590 and J. of Med. Chem., 1997, 40, 547.

Compound VIII where symbols R^1 , R^3 , R^4 are same as defined earlier was treated
5 with substituted aniline of formula IX under heating conditions in a solvent such as acetic acid and the like to obtain compound of the formula X.

The compounds of the formula X when $R^3 = H$ can be functionalized by electrophilic reagents such as but not limited to I_2 , HNO_2 , $HCHO$ which would further lead to the formation of compounds of formula X having $R^3 =$ aryl, nitro,
10 amino, amino alkyl, halo, hydroxy or cyano by using common functional group transformation procedure well known in the art.

Ester hydrolysis of compound of the formula X gave compound of formula XI. Ester hydrolysis may be carried out using standard procedure generally used in synthetic organic chemistry or well known in the art with reagents such as sodium
15 hydroxide, potassium hydroxide, lithium hydroxide or the like in solvents such as alcohol, THF or the like. Preferably, aqueous solution of sodium hydroxide and ethanol were used for this reaction.

Compound of formula XI where R^1 , R^3 , R^4 are same as defined earlier was further converted to its corresponding acid chloride using standard procedure known in
20 synthetic organic chemistry or preferably by reaction with oxalyl chloride in dichloromethane along with DMF followed by reaction with *N,O*-dimethylhydroxylamine hydrochloride and triethylamine in dichloromethane to provide compound of formula XII.

Compound of the formula XII was treated with Grignard reagent R^2MgX^1 where R^2
25 selected from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl, and X^1 is halogen gave compound of formula I, where R^2 is optionally substituted alkyl, optionally substituted

heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl. The reaction may be carried out as per the procedure given in literature such as J. Med. Chem., 2009, 52,3377.

- 5 Compound of formula XI was alternatively reacted with $\text{HNR}^5(\text{R}^6)$, HA^1R^5 , $\text{HN}(\text{R}^5)\text{OR}^6$ where R^5 , R^6 and A^1 are same as defined under the general formula I to provide compound of the formula I where R^2 is $-\text{NR}^5(\text{R}^6)$, $-\text{A}^1\text{R}^5$, $-\text{N}(\text{R}^5)\text{OR}^6$. The reaction was carried out according to the conditions known in converting carboxylic acids to amides and esters as known to one skilled in the art. The
- 10 reaction may be carried out in the presence of solvents, for example DMF, THF, a halogenated hydrocarbon such as chloroform and dichloromethane, an aromatic hydrocarbon such as xylene, benzene, toluene, or the like, in the presence of suitable base such as triethylamine, diisopropylethylamine, pyridine or mixtures thereof or the like at a temperature between 0-50°C using reagents such as 1-(3-
- 15 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1,3-dicyclohexylcarbodiimide (DCC), auxiliary reagents such as 1-hydroxy-7-azabenzotriazole (HOAT), hydroxybenzotriazole hydrate (HOBT) or the like.

- Alternatively, the compounds of the formula I where $\text{R}^3 = \text{H}$; R^2 is selected from optionally substituted alkyl, optionally substituted heteroalkyl, optionally
- 20 substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocyclyl; R^1 is optionally substituted alkyl, perhaloalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl; and R^4 is same as defined earlier was prepared from compound of the formula V where R^3 is
- 25 H, R^4 is same as defined under generic formula I, and X^1 is halogen by reacting it with compound of the formula XIII where R^1 is same as defined earlier and R^2 is same as defined earlier excluding NR^5R^6 , $-\text{A}^1\text{R}^5$, $-\text{N}(\text{R}^5)\text{OR}^6$ to give the compound XIV where R^3 is H; R^2 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl,
- 30 optionally substituted cycloalkyl or optionally substituted heterocyclyl; R^1 and R^4

are same as defined earlier in the generic formula I. The reaction may be carried out in the presence of base such as potassium carbonate, sodium hydride, preferably pulverized sodium in a solvent such as THF, an aromatic hydrocarbon such as benzene, toluene or the like, preferably toluene is used.


- 5 Cyclization of compound of formula XIV with substituted aniline of formula IX under heating conditions in a solvent such as acetic acid or the like gave compound of formula I.

Compound of the formula XIII was be prepared according to the procedure given in literature such as J. Amer. Chem. Soc. 1945, 67, 9, 1510-1512.

- 10 Compound of the formula I where R^1 is hydrogen, R^2 , R^3 and R^4 are same as defined earlier can be synthesized by adopting the chemistry described in Tetrahedron Letters, 1982, 23, 37, 3765-3768 and Helvetica Chimica Acta, 1998, 81, 7, 1207-1214.
- 15 Compound of the formula I where $R^1 = H$, R^2 , R^3 and R^4 are same as defined earlier can be converted to compound of the formula I where R^1 is Halogen, R^2 , R^3 and R^4 are same as defined earlier by halogenation. Halogenation can be carried out under a condition according to a procedure generally used in the synthetic organic chemistry using bromine, iodine, NCS, NBS, NIS, sufuryl chloride, cupric chloride,
- 20 cupric bromide or cupric iodide preferably bromine and cupric chloride using a solvent such as ethyl acetate, dichloromethane, methanol, THF, 1,4 dioxane , and preferably dichloromethane or methanol.

- Compound of formula II where R^4 is same as defined under compound I can be
- 25 prepared using process reported in the literature such as J.Med. Chem, 1985, 28, 1, 116-124, Monatshefte fur chemie, 1996, 127, 275-290, J.Med. Chem., 1997, 40, 16, 2445-2451, US 4808597 and Eur. J. of Med. Chem., 2008, 43, 8, 1730 – 1736, or the like.

Process for synthesis of some of the typical intermediates of formula II is provided hereinbelow in scheme 2.



Compound XVII was prepared starting from compounds represented by general
 5 formula XV where X¹ is halo, by esterification of carboxylic acid with alcohol in the
 presence of inorganic acid such as but not limited to catalytic H₂SO₄ under room
 temperature to heated condition as described in the literature like Journal of the
 American Chemical Society, 1944, 66, 914-17 to obtain the Compounds of
 formula XVI. The compounds of the formula XVI was treated with Grignard reagent
 10 (MeMgX¹) to provide the compounds of formula XVII. The reaction may be carried
 out but not limited to the procedure given in literature such as J. Med. Chem,
 2009, 52, 3377. The compound XVII was converted to compound of formula II
 where symbols R⁴ are same as defined for compound I by subjecting them to
 Friedal-Crafts reaction in the presence of Lewis acid as described in the literature
 15 (J. Med. Chem, 1985, 28, 1, 116 – 124).

The compounds of formula II where symbols R^4 are same as defined for compound I was prepared from compound XVIII by acetylating using base such as but not limited to triethyl amine and acetyl chloride as described in J. Med. Chem, 2000, 43, 236-249.

- 5 The compound XXIII can be prepared starting from compounds represented by general formulae XIX by treatment of substituted phenol with alkyl 2,4-dibromobutanoate in the presence of base such as K_2CO_3 under room temperature to heated condition as described in the literature such as US2010076027 to give the compound of the formula XX. The compound of formula XX was converted to
10 compound of formula XXI by cyclopropane ring formation using base such as but not limited to potassium *t*-butoxide as described in the literature such as US2010076027. The compound of formula XXI can be converted into compound of formula XXII using reducing reagent such as but not limited to $LiAlH_4$ as described in the literature Tetrahedron, 1994, 50, 15, 4311-4322; which was de-protected by
15 method using reagents such as ceric ammonium nitrate, Trifluoromethane sulfonate BF_3 -etherate but preferably by hydrogenation using catalytic palladium on carbon to give compound of formula XXIII. The compound XXIII was converted to compound of formula II where symbols R^4 are same as defined for compound I by subjecting them to Mitsunobu reaction in the presence of reagent such as but
20 not limited to Diethyl azo dicarboxylate as described in the literature (Bioorganic & Medicinal Chemistry Letters, 2009, 19(3), 854 – 859).

The intermediates and the compounds of the present invention are obtained in pure form in a manner known *per se*, for example by distilling off the solvent in vacuum and re-crystallizing the residue obtained from a suitable solvent, such as
25 pentane, diethyl ether, isopropyl ether, chloroform, dichloromethane, ethyl acetate, acetone or their combinations or subjecting it to one of the purification methods, such as column chromatography (eg. flash chromatography) on a suitable support material such as alumina or silica gel using eluent such as dichloromethane, ethyl acetate, hexane, methanol, acetone and their combinations. Preparative LC-MS
30 method is also used for the purification of molecules described herein.

Salts of compound of formula I are obtained by dissolving the compound in a suitable solvent, for example in a chlorinated hydrocarbon, such as methyl chloride or chloroform or a low molecular weight aliphatic alcohol, for example, ethanol or isopropanol, which was then treated with the desired acid or base as described in Berge S.M. et al. "Pharmaceutical Salts, a review article in Journal of Pharmaceutical sciences volume 66, page 1-19 (1977)" and in handbook of pharmaceutical salts properties, selection, and use by P.H.Einrich Stahland Camille G.wermuth , Wiley- VCH (2002).

The stereoisomers of the compounds of formula I of the present invention may be prepared by stereospecific syntheses or resolution of the achiral compound using an optically active amine, acid or complex forming agent, and separating the diastereomeric salt/complex by fractional crystallization or by column chromatography.

The present invention further provides a pharmaceutical composition, containing the compounds of the general formula (I) as defined above, its tautomeric forms, its stereoisomers, its isotopes, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates and its co-crystals in combination with the usual pharmaceutically employed carriers, diluents and the like are useful for the treatment and/or prophylaxis of diseases or disorder or condition such as Alzheimer's disease (AD), mild cognitive impairment (MCI), senile dementia, vascular dementia, dementia of Parkinson's disease, attention deficit disorder, attention deficit hyperactivity disorder (ADHD), dementia associated with Lewy bodies, AIDS dementia complex (ADC), Pick's disease, dementia associated with Down's syndrome, Huntington's disease, cognitive deficits associated with traumatic brain injury (TBI), cognitive and sensorimotor gating deficits associated with schizophrenia, cognitive deficits associated with bipolar disorder, cognitive impairments associated with depression, acute pain, post-surgical or post-operative pain, chronic pain, inflammation, inflammatory pain, neuropathic pain,

smoking cessation, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, arthritis, rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, pouchitis, inflammatory bowel disease, celiac disease, periodontitis, sarcoidosis, pancreatitis, organ transplant rejection, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, septic shock, toxic shock syndrome, sepsis syndrome, depression, and rheumatoid spondylitis.

- 10 The present invention also provides a pharmaceutical composition, containing the compounds of the general formula (I) as defined above, its tautomeric forms, its stereoisomers, its isotopes, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates and its co-crystals in combination with the usual pharmaceutically employed carriers, diluents and the like are useful for the treatment and/or prophylaxis of diseases or disorder or condition classified or diagnosed as major or minor neurocognitive disorders, or disorders arising due to neurodegeneration.


- 20 The present invention also provide method of administering a compound of formula I, as defined hereinabove in combination with or as adjunct to medications used in the treatment of attention deficit hyperactivity disorders, schizophrenia, and other cognitive disorders such as Alzheimer's disease, Parkinson's dementia, vascular dementia or dementia associated with Lewy bodies, traumatic brain injury.

- 25 The present invention also provide method of administering a compound of formula I, as defined hereinabove in combination with or as an adjunct to acetylcholinesterase inhibitors, disease modifying drugs or biologics for neurodegenerative disorders, dopaminergic drugs, antidepressants, typical or an atypical antipsychotic.


Accordingly, compound of formula I is useful for preventing or treating a disorder mediated by nicotinic acetylcholine receptors. Such compounds can be administered to a subject having such a disorder or susceptible to such disorders in a therapeutically effective amount. The compounds are particularly useful for a method of treating a mammal having a condition where modulation of nicotinic acetylcholine receptor activity is of therapeutic benefit, wherein the method is accomplished by administering a therapeutically effective amount of a compound of formula I to a subject having, or susceptible to, such a disorder. The term 'subject' used herein can be defined as any living organism capable of expressing $\alpha 7$ subunit of nicotinic acetylcholine receptor including mammals.

The following examples are provided to further illustrate the present invention. All ^1H NMR spectra were determined in the solvents indicated and chemical shifts are reported in δ units downfield from the internal standard tetramethylsilane (TMS) and interproton coupling constants are reported in Hertz (Hz).

Example 1: Preparation of 4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide.



Step 1: 2-Bromo-1-(4,4-dimethylchroman-6-yl)ethanone




To a stirred solution of 1-(4,4-dimethylchroman-6-yl)ethanone (prepared according to the procedure reported in J. Med. Chem, 1985, 28, 1, 116-124, 2.0g, 9.80 mmol) in methanol (30 ml.) was added bromine (1.57g, 0.5 ml, 9.80 mmol) in a dropwise manner at 10°C. The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Water (10 ml) was added to it and resultant mixture was stirred for 45 minutes at room temperature. Solvent was evaporated at reduced pressure. Residue so obtained was taken in ethyl acetate (100 ml), washed with water (25 ml) followed by brine (25 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 20% ethyl acetate in hexanes as an eluent to yield the title compound (2.3 g, 83%)

MS: *m/z* 283 (M+1)

¹H NMR (CDCl₃, 400 MHz): δ 7.98 (d, *J*=2.4 Hz, 1H), 7.70 (dd, *J*=8.4, 2.4 Hz, 1H), 6.82 (d, *J*=8.4 Hz, 1H), 4.38 (s, 2H), 4.26 (dt, *J*=4.4, 1.2 Hz, 2H), 1.85 (dt, *J*=4.4, 1.2 Hz, 2H), 1.37 (s, 6H).

Step 2: 3-Acetyl-1-(4,4-dimethylchroman-6-yl)hexane-1,4-dione




To the stirred solution of pulverized sodium (0.2g , 8.63 mmol) in toluene (40 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.894g, 7.85 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 2-bromo-1-(4,4-dimethylchroman-6-yl)ethanone (step 1, 2.0g , 7.07 mmol) in toluene (10 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (15 ml) and extracted with ethyl acetate (2x100 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 20% ethyl acetate in hexanes as an eluent to yield the title compound (1.4g, 62.78%).

MS: *m/z* 317 (M+1)

¹HNMR (CDCl₃, 400 MHz): δ 7.90 (d, *J*=2.4Hz, 1H), 7.68 (dd, *J*=8.4,2.4 Hz, 1H), 6.79 (d, *J*=8.4Hz, 1H), 4.3 (t, *J*=6.8Hz, 1H), 4.25 (dt, *J*=4.4, 1.2 Hz, 2H), 3.52 (d, *J*=6.8Hz, 2H), 2.67 (q, *J*=7.2Hz, 2H), 2.31 (s, 3H), 1.84 (dt, *J*=4.4, 1.2 Hz, 2H), 1.33 (s, 6H), 1.08 (t, *J*=7.2Hz, 3H).

Step 3: 4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide

20




A mixture of 3-acetyl-1-(4,4-dimethylchroman-6-yl)hexane-1,4-dione (step 2, 1.3g , 4.11 mmol) and 4-aminobenzenesulfonamide (0.7g, 4.11mmol) in acetic acid (5 ml) was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in
 5 solution of ammonia in chloroform (20 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (100 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica
 10 gel (100-200 mesh) using 4% methanol in dichloromethane as an eluent to yield the title compound (0.460 g, 24.8%)

MS: *m/z* 453 (M+1)

¹HNMR (CDCl₃, 400 MHz): δ 7.95 (d, *J*=8.8Hz, 2H), 7.26 (d, *J*=8.8,Hz, 2H), 6.89 (dd, *J*=8.4, 2.0 Hz, 1H), 6.64 (m, 3H), 5.07 (bs, exchanged with D₂O 2H), 4.09 (t, *J*=5.2Hz, 2H), 2.85 (q, *J*=7.2Hz, 2H), 2.41 (s, 3H), 1.70 (t, *J*= 5.2 Hz, 2H), 1.19 (t, *J*=7.2Hz, 3H), 1.00 (s, 6H).

Example 2: Preparation of 4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide [Alternative Method]

Step 1: Ethyl 2-acetyl-4-(4,4-dimethylchroman-6-yl)-4-oxobutanoate




20

To the stirred solution of pulverized sodium (0.35g, 15.61 mmol) in toluene (40 ml) was added ethyl-3-oxobutanoate (3.05g, 2.97 ml, 23.46 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 2-

bromo-1-(4,4-dimethylchroman-6-yl)ethanone (4.41g , 15.61 mmol) in toluene (25ml) and reaction mixture was stirred at room temperature for 2 hr . The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (30 ml) and extracted with ethyl acetate (2x250 ml) and the combined
 5 organic layer was dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using DCM as an eluent to yield the title compound (3.5g, 67.3%).

MS: m/z 333 (M+1)


10 **Step 2:** Ethyl 5-(4,4-dimethylchroman-6-yl)-2-methyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylate



A mixture of ethyl 2-acetyl-4-(4,4-dimethylchroman-6-yl)-4-oxobutanoate (Step 1, 3.5g, 10.53 mmol) and 4-aminobenzenesulfonamide (2.18g, 12.64 mmol) in acetic acid (35 ml) was heated at 110° C for 15 hr. The completion of reaction was monitored by TLC. Reaction mixture was concentrated at reduced pressure. Ethyl acetate (250 ml) was added to the residue, washed with water (1x 30 ml). Organic layer was dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced
 20 pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 0.1% methanol in dichloromethane as an eluent to yield the title compound (2.5 g, 50.80%)

MS: m/z 469 (M+1)

Step 3: 5-(4,4-dimethylchroman-6-yl)-2-methyl-1-(4-sulfamoylphenyl)-1*H*-pyrrole-3-carboxylic acid




5

Ethyl 5-(4,4-dimethylchroman-6-yl)-2-methyl-1-(4-sulfamoylphenyl)-1*H*-pyrrole-3-carboxylate (Step 2, 2.5g , 5.34 mmol) was suspended in ethanol (100 ml) and treated with 2M solution of NaOH (25 ml) at 0°C. the reaction mixture was refluxed for 3 hr. The completion of reaction was monitored by TLC. Reaction mixture was concentrated at reduced pressure. Residue was diluted with water (10 ml) and neutralized with 10 % HCl upto pH7, aqueous layer was extracted with ethyl acetate (2 x 100 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a product. (1.7g, 72.3%)

15 MS: m/z 441 (M+1)

Step 4: 1-(4-(*N*-((dimethylamino)methylene)sulfamoyl)phenyl)-5-(4,4-dimethylchroman-6-yl)-*N*-methoxy-*N*,2-dimethyl-1*H*-pyrrole-3-carboxamide




Oxalyl chloride (0.98g, 0.65ml, 7.72 mmol) was added dropwise at 0°C to a solution of 5-(4,4-dimethylchroman-6-yl)-2-methyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylic acid (step 3, 1.7g, 3.86 mmol) in dichloromethane (100 ml) and DMF (0.56g, 0.59 ml, 7.72 mmol). Mixture was allowed to come at room temperature and stirred for 2 hr. under nitrogen atmosphere. The completion of reaction was monitored by TLC. The mixture was concentrated under reduced pressure and used directly for further reaction.

To this residue was added *N,O*-dimethylhydroxylamine hydrochloride (0.75g, 7.72 mmol) in dry dichloromethane (50 ml) at 0°C followed by the addition of triethylamine (1.56g, 2.05 ml, 15.44 mmol) under stirring. The reaction mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. The solvent was removed under reduced pressure. The residue so obtained was taken in dichloromethane (100 ml), washed with water (2x 10 ml.) and organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product. This crude product was purified by column chromatography over silica gel (100-200 mesh) using 0.2% methanol in dichloromethane as an eluent to yield the title compound (1.67g, 80.6%).

MS: m/z 539 (M+1)

Step 5: 4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide




5 To a solution of 1-4-(*N*-((dimethylamino)methylene)sulfamoyl)phenyl)-5-(4,4-dimethylchroman-6-yl)-*N*-methoxy-*N*,2-dimethyl-1*H*-pyrrole-3-carboxamide (Step 4, 1.67g , 3.10 mmol) in anhydrous THF (25 ml) at 0°C, Grignard reagent [ethyl magnesium bromide, 2.06g , 15.5 ml (1 M soln. in THF), 15.52 mmol] was added dropwise and reaction mixture was heated to reflux for 30 minutes. The
10 completion of reaction was monitored by TLC. After cooling, reaction mixture was quenched by addition of solution of saturated ammonium chloride (20 ml) and extracted with ethyl acetate (2 x100 ml) . Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-
15 200 mesh) using 0.1% methanol in dichloromethane as an eluent to yield the title compound which was finally purified by preparative HPLC (0.100g, 7.1 %)

MS: *m/z* 453 (M+1)

¹HNMR (CDCl₃, 400 MHz): δ 7.95 (d, *J*=8.8Hz, 2H), 7.27 (d, *J*=8.8,Hz, 2H), 6.90 (dd, *J*=8.4, 2.0 Hz, 1H), 6.65 (m, 3H), 4.90 (bs, exchanged with D₂O 2H), 4.11 (t, *J*=5.2Hz, 2H), 2.86 (q, *J*=7.2Hz, 2H), 2.44 (s, 3H), 1.71 (t, *J*= 5.2 Hz, 2H), 1.21(t, *J*=7.2Hz, 3H) , 1.02 (s, 6H).

Example 3: Following compounds of the present inventions were prepared using a process analogous to Example 1 and 2 by appropriately changing the reactants required.


4-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 427 (M+1),

^1H NMR (CDCl_3 , 400 MHz): δ 7.96 (d, $J=8.4\text{Hz}$, 2H), 7.28 (d, $J=8.4\text{Hz}$, 2H), 6.64-6.66 (m, 2H), 6.58 (d, $J=2.0\text{ Hz}$, 1H), 6.40 (dd, $J=8.4, 2.0\text{ Hz}$, 1H), 4.87 (bs, exchanged with D_2O 2H), 4.19-4.22 (m, 4H), 2.86 (q, $J=7.2\text{Hz}$, 2H), 2.42 (s, 3H), 1.20 (t, $J=7.2\text{Hz}$, 3H).


4-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5-dimethyl-4-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 441 (M+1);

^1H NMR (CDCl_3 , 400 MHz): δ 7.87 (d, $J=8.4\text{Hz}$, 2H), 7.19 (d, $J=8.4\text{Hz}$, 2H), 6.67 (d, $J=8.0\text{ Hz}$, 1H), 6.56 (d, $J=2.0\text{ Hz}$, 1H), 6.39 (dd, $J=8.0, 2.0\text{ Hz}$, 1H), 4.88 (bs, exchanged with D_2O 2H), 4.13-4.22 (m, 4H), 2.86 (q, $J=7.2\text{Hz}$, 2H), 2.33 (s, 3H),
5 2.24 (s, 3H), 1.20 (t, $J=7.2\text{Hz}$, 3H).


Ethyl 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,4-dimethyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylate



MS: m/z 457 (M+1),

10 ^1H NMR (CDCl_3 , 400 MHz): δ 7.87 (d, $J=8.4\text{Hz}$, 2H), 7.17 (d, $J=8.4\text{Hz}$, 2H), 6.65 (d, $J=8.4\text{ Hz}$, 1H), 6.56 (d, $J=2.0\text{ Hz}$, 1H), 6.39 (dd, $J=8.4, 2.0\text{ Hz}$, 1H), 4.95 (bs, exchanged with D_2O 2H), 4.22 (q, $J=6.8\text{Hz}$, 2H), 4.14-4.20 (m, 4H), 2.35 (s, 3H),
2.22 (s, 3H), 1.36 (t, $J=6.8\text{Hz}$, 3H).


4-(2-methyl-3-propionyl-5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrol-1-yl)benzenesulfonamide.
15




MS: m/z 423 (M+1),

^1H NMR (CDCl_3 , 400 MHz): δ 7.95 (d, $J=8.4\text{Hz}$, 2H), 7.28 (d, $J=8.4\text{Hz}$, 2H), 6.80-6.83 (m, 2H), 6.67 (s, 1H), 6.59 (dd, $J=8.0$, 2.0 Hz, 1H), 4.99 (bs, exchanged with D_2O 2H), 2.87 (q, $J=7.2\text{Hz}$, 2H), 2.60-2.68 (m, 4H), 2.42 (s, 3H), 1.72-1.75 (m, 4H),
5 1.20 (t, $J=7.2\text{Hz}$, 3H).

Example 4: Preparation of 4-(5-(2,3-dihydro-1H-inden-4-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.



10 **Step 1:** 2-bromo-1-(2,3-dihydro-1H-inden-4-yl)ethanone




To a stirred solution of 1-(2,3-dihydro-1H-inden-4-yl)ethanone (prepared according to the procedure reported in Monatshefte für Chemie 1996, 127, 275-290, 0.8 gm, 5.00 mmol) in diethyl ether (8 ml) were added AlCl_3 (0.73 gm, 5.5 mmol) and
15 bromine (0.96 gm, 0.31 ml, 6.00 mmol) in a drop wise manner at 0°C . The resulting mixture was stirred at room temperature for 1 hr. The completion of reaction was monitored by TLC. Reaction mixture was poured into cold water (10 ml). Aqueous layer was extracted with ethyl acetate (2 x 30 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at
20 reduced pressure to get a crude product; which was purified by column

chromatography using 1% ethyl acetate in hexanes as an eluent to yield the title compound (0.76 gm, 63.8%).

MS: m/z 240 (M+1),

^1H NMR (CDCl_3 , 400 MHz): δ 7.66 (d, $J=7.2$ Hz, 1H), 7.43 (d, $J=7.2$ Hz, 1H), 7.23-7.27 (m, 1H), 4.49 (s, 2H), 3.25 (t, $J=7.6$ Hz, 2H), 2.92 (t, $J=7.6$ Hz, 2H), 2.08 (quintet, $J=7.6$ Hz, 2H).

Step 2: 3-acetyl-1-(2,3-dihydro-1H-inden-4-yl)hexane-1,4-dione




To the stirred solution of pulverized sodium (0.046 gm, 2.00 mmol) in toluene (5 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.21 gm, 1.85 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 2-bromo-1-(2,3-dihydro-1H-inden-4-yl)ethanone (step 1, 0.4 gm, 1.67 mmol) in toluene (5 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (5 ml) and extracted with ethyl acetate (2x30 ml) and the combined organic layer was dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 10% ethyl acetate in hexanes as an eluent to yield the title compound (0.196 gm, 39.12%).

MS: m/z 273 (M+1),

^1H NMR (CDCl_3 , 400 MHz): δ 7.72 (d, $J=7.2$ Hz, 1H), 7.41 (d, $J=7.2$ Hz, 1H), 7.23-7.26 (m, 1H), 4.36 (t, $J=7.2$ Hz, 1H), 3.56 (d, $J=7.2$ Hz, 2H), 3.23 (t, $J=7.6$ Hz, 2H),

2.91 (t, $J=7.6$ Hz, 2H), 2.69 (q, $J=7.6$ Hz, 2H), 2.31 (s, 3H), 2.07 (quintet, $J=7.2$ Hz, 2H), 1.08 (t, $J=7.2$ Hz, 3H).

Step 3: 4-(5-(2,3-dihydro-1H-inden-4-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




5

To the solution of 3-acetyl-1-(2,3-dihydro-1H-inden-4-yl)hexane-1,4-dione (step 2, 0.18 gm, 0.68 mmol) in acetic acid (5 ml) was added 4-aminobenzenesulfonamide (0.12 gm, 0.68 mmol) at room temperature. Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (10 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (30 ml) was added to the residue, washed with water (5 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 5% methanol in DCM as an eluent to yield the title compound (0.041 gm, 14.8%).


MS: m/z 409 (M+1),

¹HNMR (DMSO, 400 MHz): δ 7.80 (d, $J=8.4$ Hz, 2H), 7.48 (bs-exchanges with D₂O, 2H), 7.41 (d, $J=8.4$ Hz, 2H), 7.07 (d, $J=7.6$ Hz, 1H), 6.93 (t, $J=7.6$ Hz, 1H), 6.79 (s, 1H), 6.64 (d, $J=7.6$ Hz, 1H), 2.77-2.85 (m, 6H), 2.34 (s, 3H), 1.91 (quintet, $J=7.2$ Hz, 2H), 1.08 (t, $J=7.2$ Hz, 3H).

Example 5: Preparation of 4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.




5 **Step 1:** 2-bromo-1-(2,2-dimethylchroman-6-yl)ethanone



To a stirred solution of 1-(2,2-dimethylchroman-6-yl)ethanone (prepared according to the procedure reported in J. Med. Chem., 1997, 40, 16, 2445-2451, 2.5 gm, 12.25 mmol) in methanol (25 ml) was added bromine (1.96 gm, 0.63 ml, 12.25 mmol) in a drop wise manner at 0°C. The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was concentrated at reduced pressure and dissolved in DCM (100 ml). Organic layer was washed with water (2x 25 ml), dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 1% ethyl acetate in hexanes as an eluent to yield the title compound (1.50 gm, 43.22%).

MS: m/z 284 ($M+1$),

$^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.71-7.76 (m, 2H), 6.80 (d, $J=8.4$ Hz, 1H), 4.35 (s, 2H), 2.82 (t, $J=6.8$ Hz, 2H), 1.84 (t, $J=6.8$ Hz, 2H), 1.35 (s, 6H).


Step 2: 3-acetyl-1-(2,2-dimethylchroman-6-yl)hexane-1,4-dione

To the stirred solution of pulverized sodium (0.37 gm, 16.08 mmol) in toluene (10 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 1.82 gm, 15.96 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 2-bromo-1-(2,2-dimethylchroman-6-yl)ethanone (step 1, 3.0 gm, 10.60 mmol) in toluene (10 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (15 ml) and extracted with ethyl acetate (2x 100 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 5% ethyl acetate in hexanes as an eluent to yield the title compound (1.00 gm, 29.9%).

MS: *m/z* 317 (M+1),

¹HNMR (CDCl₃, 400 MHz): δ 7.67-7.77 (m, 2H), 6.72-6.79 (m, 1H), 4.36 (t, *J*=6.8 Hz, 1H), 3.51 (d, *J*=6.8 Hz, 2H), 2.72-2.85 (m, 4H), 2.31 (s, 3H), 1.82 (q, *J*=7.2 Hz, 2H), 1.35 (s, 6H), 1.06 (t, *J*=7.2 Hz, 3H).

Step 3: 4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




To the solution of 3-acetyl-1-(2,2-dimethylchroman-6-yl)hexane-1,4-dione (step 2, 0.33 gm, 1.05 mmol) in acetic acid (5 ml) was added 4-aminobenzenesulfonamide (0.22 gm, 1.25 mmol) at room temperature. Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (10 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (30 ml) was added to the residue, washed with water (5 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 5% methanol in DCM as an eluent to yield the title compound (0.10 gm, 21.27%).


MS: *m/z* 453 (M+1),

¹HNMR (DMSO, 400 MHz): δ 7.87 (d, *J*=8.4 Hz, 2H), 7.50 (bs-exchanges with D₂O, 2H), 7.44 (d, *J*=8.4 Hz, 2H), 6.93 (d, *J*=2.0 Hz, 1H), 6.78 (s, 1H), 6.57 (dd, *J*=8.4, 2.0 Hz, 1H), 6.47 (d, *J*=8.4 Hz, 1H), 2.82 (q, *J*=7.2 Hz, 2H), 2.60 (t, *J*=6.8 Hz, 2H), 2.31 (s, 3H), 1.70 (t, *J*=6.8 Hz, 2H), 1.22 (s, 6H), 1.07 (t, *J*=7.2 Hz, 3H).

Example 6: Preparation of 4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.



Step 1: Methyl 3-(2-fluorophenoxy)propanoate




To a stirred solution of 3-(2-fluorophenoxy)propanoic acid (prepared according to the procedure reported in WO2010013794, 14.0 gm, 76.08 mmol) in methanol (140 ml) was added thionyl chloride (13.57 gm, 8.5 ml, 114.12 mmol) in a drop wise manner at 0°C. The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was concentrated at reduced pressure and dissolved in Ethyl acetate (300 ml). Organic layer was washed with water (2x 50 ml), dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 20% ethyl acetate in hexanes as an eluent to yield the title compound (12.9 gm, 85.66%).

MS: m/z 221 ($M+23$),

^1H NMR (CDCl_3 , 400 MHz): δ 6.88 – 7.09 (m, 4H), 4.32 (t, $J=6.4$ Hz, 2H), 3.72 (s, 3H), 2.84 (t, $J=6.4$ Hz, 2H).

Step 2: 4-(2-fluorophenoxy)-2-methylbutan-2-ol




To a stirred solution of methyl 3-(2-fluorophenoxy)propanoate (Step-1, 12.0 gm, 60.60 mmol) in THF (25 ml) was added methyl magnesium bromide (21.67 gm, 60.72 ml 3M solution in diethyl ether, 181.80 mmol) in a drop wise manner at 0°C under nitrogen atmosphere. The resulting mixture was stirred at 90°C for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was quenched by addition of saturated NH₄Cl solution (100 ml). Aquous layer was extracted with ethyl acetate (2x 200 ml). Organic layers was washed with water (2x 50 ml), dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 12% ethyl acetate in hexanes as an eluent to yield the title compound (8.60 gm, 71.66%).

MS: *m/z* 221 (M+23),

¹HNMR (CDCl₃, 400 MHz): δ 6.88 – 7.09 (m, 4H), 4.24 (t, *J*=6.4 Hz, 2H), 2.35 (bs, exchanges with D₂O 1H), 2.02 (t, *J*=6.4 Hz, 2H), 1.31 (s, 6H).

Step 3: 8-fluoro-4,4-dimethylchroman




To a stirred solution of AlCl₃ (8.67 gm, 65.05 mmol) in nitromethane (50 ml) was added solution of 4-(2-fluorophenoxy)-2-methylbutan-2-ol (Step-2, 8.5 gm, 43.36 mmol) in nitromethane (20 ml) in a drop wise manner at 0°C. The resulting mixture was stirred at room temperature for 3 hr. The completion of reaction was monitored by TLC. Reaction mixture was quenched with 2N HCl (50 ml) at 0°C.

Aqueous layer was extracted with ethyl acetate (2 x 100 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 1% ethyl acetate in hexanes as an eluent to yield the title compound (5.80 gm, 74.35%).

MS: m/z No ionization,

^1H NMR (CDCl_3 , 400 MHz): δ 7.03 – 7.76 (dt, $J=1.6$ Hz, 8.0 Hz, 1H), 6.85 – 6.88 (m, 1H), 6.77 – 6.8 (m, 1H), 4.24-4.26 (m, 2H), 1.85-1.87 (m, 2H), 1.33 (s, 6H).

Step 4: 2-bromo-1-(8-fluoro-4,4-dimethylchroman-6-yl)ethanone



10


To a stirred solution of AlCl_3 (4.88 gm, 36.73 mmol) in DCE (60 ml) was added solution of 8-fluoro-4,4-dimethylchroman (Step-3, 5.8 gm, 32.22 mmol) in DCE (20 ml) and 2-bromoacetyl bromide (7.80 gm, 3.35 ml, 38.66 mmol) in a drop wise manner at 0°C . The resulting mixture was stirred at room temperature for 3 hr.

15 The completion of reaction was monitored by TLC. Reaction mixture was quenched with water (70 ml) at 0°C . Aqueous layer was extracted with ethyl acetate (2 x 100 ml). Organic layers washed with 1N HCl (50 ml), water (50 ml). Organic layer separated was dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column

20 chromatography using 6% ethyl acetate in hexanes as an eluent to yield the title compound (6.20 gm, 64.18%).

MS: m/z 301 ($\text{M}+1$),

^1H NMR (CDCl_3 , 400 MHz): δ 7.75 – 7.76 (m, 1H), 7.28 (d, $J=11.2$ Hz, 2 Hz, 1H), 4.33 -4.35 (m, 4H), 1.89 (dd, $J=6.0$, 5.6 Hz, 2H), 1.37 (s, 6H).


Step 5: 3-acetyl-1-(8-fluoro-4,4-dimethylchroman-6-yl)hexane-1,4-dione

To the stirred solution of pulverized sodium (0.057 gm, 2.49 mmol) in toluene (5 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.23 gm, 1.99 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 2-bromo-1-(8-fluoro-4,4-dimethylchroman-6-yl)ethanone (step 4, 0.5 gm, 1.66 mmol) in toluene (5 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (10 ml) and extracted with ethyl acetate (2x 30 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 20% ethyl acetate in hexanes as an eluent to yield the title compound (0.32 gm, 60.37%).

MS: *m/z* 373 (M+39),

¹HNMR (CDCl₃, 400 MHz): δ 7.34-7.43 (m, 1H), 7.12-7.21 (m, 1H), 5.12-5.15(m, 1H), 4.12-4.34 (m, 4H), 2.04 (s, 3H), 1.84-1.91 (m, 4H), 1.35 (s, 6H), 1.21 (t, *J*=7.2 Hz, 3H).

Step 6: 4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



To the solution of 3-acetyl-1-(8-fluoro-4,4-dimethylchroman-6-yl)hexane-1,4-dione (step 2, 0.30 gm, 0.94 mmol) in acetic acid (10 ml) was added 4-aminobenzenesulfonamide (0.24 gm, 1.41 mmol) at room temperature. Reaction mixture was heated at 110° C for 24 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (10 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (30 ml) was added to the residue, washed with water (5 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 30% ethyl acetate in hexanes as an eluent to yield the title compound (0.54 gm, 12.27%).


MS: *m/z* 471 (M+1),

¹HNMR (CDCl₃, 400 MHz): δ 7.99 (d, *J*=8.8 Hz, 2H), 7.28 (d, *J*=8.8 Hz, 2H), 6.74 (dd, *J*=11.6, 2.0 Hz, 1H), 6.66 (s, 1H), 6.42 (t, *J*=2.0 Hz, 1H), 5.02 (bs-exchanges with D₂O, 2H), 4.19 (t, *J*=5.2 Hz, 2H), 2.86 (q, *J*=7.2 Hz, 2H), 2.43 (s, 3H), 1.75 (t, *J*=5.2 Hz, 2H), 1.21 (t, *J*=7.2 Hz, 3H), 1.02 (s, 6H).

Example 7: Preparation of


4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

53




And

4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.



5

Step 1: 1-(4,4-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)ethanone




To a stirred solution of 4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline (prepared according to the procedure reported in WO20050037214 A2, 4.0 gm, 24.84 mmol) in DCM (100 ml.) was added triethyl amine (2.76 gm, 3.9 ml, 27.32 mmol) in a dropwise manner at 0°C followed by addition of acetyl chloride (2.14 gm, 1.9 ml, 27.32 mmol). The resulting mixture was stirred at room temperature for 2 hr.

The completion of reaction was monitored by TLC. Reaction mixture was diluted with DCM (100 ml), washed with water (2x 25 ml) followed by brine (25 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified
 5 by column chromatography over silica gel (100-200 mesh) using 2.5% methanol in DCM as an eluent to yield the title compound (4.9 g, 97%)

MS: *m/z* 204 (M+1),


¹HNMR (DMSO, 400 MHz): δ 7.04-7.36 (m, 4H), 4.76 (s, 2H), 3.42 (s, 2H), 2.18 (s, 3H), 1.30 (s, 3H), 1.27 (s, 3H).

10 **Step 2:** Mixture of 1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromoethanone



And

1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-bromoethanone




15

To a stirred solution of AlCl₃ (1.84 gm, 13.79 mmol) in DCE (30 ml) was added solution of 1-(4,4-dimethyl-3,4-dihydroisoquinolin-2(1H)-yl)ethanone (Step-1, 2.0 gm, 9.85 mmol) in DCE (10 ml) and 2-bromoacetyl bromide (2.60 gm, 1.13 ml, 12.80 mmol) in a drop wise manner at 0°C. The resulting mixture was stirred at
 20 room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was poured into cold water (50 ml). Aqueous layer was extracted


with DCM (2 x 100 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 2.5% methanol in DCM as an eluent to yield mixture of 1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromoethanone and 1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-bromoethanone (2.1 gm, 65.83%)

Step 3: Mixture of 3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)hexane-1,4-dione



And


3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)hexane-1,4-dione



To the stirred solution of pulverized sodium (0.22 gm , 9.42 mmol) in toluene (40 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.98 gm, 8.56 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added


solution of mixture of the 1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-bromoethanone and 1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-bromoethanone (step 2, 2.5 gm , 7.71 mmol) in toluene (10 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (15 ml) and extracted with ethyl acetate (2x100 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 2.5% methanol in DCM as an eluent to yield mixture of 3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)hexane-1,4-dione and 3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)hexane-1,4-dione (1.45 gm, 47.5%).

Step 4: 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




And

4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



To the solution of the mixture of 3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)hexane-1,4-dione and 3-acetyl-1-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)hexane-1,4-dione (step 3, 1.4 gm , 3.92 mmol) in acetic acid (5 ml) was added 4-aminobenzenesulfonamide (0.68 gm, 3.92 mmol) at room temperature. Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (20 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (100 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 50 % ethyl acetate in hexanes as an eluent to yield mixture of the 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide and 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide. The mixture was separated by preparative HPLC to yield the first title compound (0.31 gm, 16.0%) and second title compound (0.21 gm, 10.89%).


First title compound: 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 494 ($M+1$),

^1H NMR (DMSO, 400 MHz): δ 7.89-7.92 (m, 2H), 7.54 (bs-exchanges with D_2O , 2H), 7.49 (d, $J=8.4$ Hz, 2H), 7.18 (d, $J=8.0$ Hz, 1H), 7.01 (s, 1H), 6.92 (d, $J=2.4$ Hz, 1H),
 5 6.72-6.74 (m, 1H), 4.56 (s, 2H), 3.42 (s, 2H), 2.84 (q, $J=7.2$ Hz, 2H), 2.30 (s, 3H), 2.05 (s, 3H), 1.17 (s, 3H), 1.11 (s, 3H), 1.05 (t, $J=7.2$ Hz, 3H).

Second title compound: 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




10

MS: m/z 494 ($M+1$),

^1H NMR (DMSO, 400 MHz): δ 7.89 (d, $J=8.4$ Hz, 2H), 7.51 (bs-exchanges with D_2O , 2H), 7.48 (d, $J=8.4$ Hz, 2H), 7.05-7.12 (m, 2H), 6.94 (s, 1H), 6.78-6.81 (m, 1H), 4.57
 15 (s, 2H), 3.17 (s, 2H), 2.85 (q, $J=7.2$ Hz, 2H), 2.34 (s, 3H), 2.04 (s, 3H), 1.08 (t, $J=7.2$ Hz, 3H), 0.94 (s, 3H), 0.89 (s, 3H).

Example 8: Preparation of 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.




To the solution of the 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (First title compound of step 4 in Example-7, 0.2 gm, 0.40 mmol) in acetonitrile (8 ml) was 6M HCl (10 ml) at room temperature. Reaction mixture was heated at 80° C for 15 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (20 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (50 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by preparative HPLC to yield the title compound (0.060 gm, 32.96%).

MS: *m/z* 452 (M+1),

¹HNMR (DMSO, 400 MHz): δ 8.23 (bs-exchanges with D₂O, 1H), 7.89 (d, *J*=8.4 Hz, 2H), 7.57 (bs-exchanges with D₂O, 2H), 7.19 (d, *J*=8.4 Hz, 2H), 6.88 (s, 1H), 6.85 (d, *J*=2.0 Hz, 1H), 6.76 (dd, *J*=8.4, 2.0 Hz, 2H), 3.81 (s, 2H), 2.84 (q, *J*=7.2 Hz, 2H), 2.78 (s, 2H), 2.30 (s, 3H), 1.17 (s, 6H), 1.05 (t, *J*=7.2 Hz, 3H).


Example 9: Preparation of 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide.



5


And

4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide.



Step 1: Methyl 4-bromo-2-(2-((4-methoxybenzyl)oxy)phenoxy)butanoate

10




To a stirred solution of 2-((4-methoxybenzyl)oxy)phenol (prepared according to the procedure reported in JOC, 1994, 59, 22, 6567-6587, 10.0 gm , 43.48 mmol) in DMF (100 ml) were added K₂CO₃ (7.81 gm, 56.52 mmol) and methyl 2,4-

dibromobutanoate (14.58 gm, ml, 56.52 mmol) at 25°C. The resulting mixture was stirred at 150°C for 3 hr. The completion of reaction was monitored by TLC. Reaction mixture was diluted with ethyl acetate (200 ml), washed with water (2x 50 ml) followed by brine (25 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 10% ethyl acetate in hexanes as an eluent to yield the title compound (10.0 g, 56.24%)

MS: *m/z* 410 (M+1),

¹HNMR (CDCl₃, 400 MHz): δ 7.34 (d, *J*=8.4 Hz, 2H), 6.90-6.98 (m, 6H), 5.00-5.07 (m, 2H), 4.78 (dd, *J*=8.8. 4.0 Hz, 1H), 3.81 (s, 3H), 3.70 (s, 3H), 3.53-3.57 (m, 2H), 2.39-2.52 (m, 2H).

Step 2: Methyl 1-(2-((4-methoxybenzyl)oxy)phenoxy)cyclopropanecarboxylate



15

To a stirred solution of methyl 4-bromo-2-(2-((4-methoxybenzyl)oxy)phenoxy)butanoate (Step-1, 8.0 gm, 19.60 mmol) in THF (100 ml) was added potassium t-butoxide (2.41 gm, 21.56 mmol) at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 3 hr. The completion of reaction was monitored by TLC. Excess of reagent was quenched with saturated NH₄Cl solution (20 ml) at 0°C. Aqueous layer was extracted with ethyl acetate (2 x 150 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 25% ethyl acetate in hexanes as an eluent to yield the title compound (2.5 g, 38.88%)


25

MS: m/z 351 (M+23),

^1H NMR (CDCl_3 , 400 MHz): δ 7.34 (d, $J=8.4$ Hz, 2H), 6.84-6.97 (m, 6H), 5.06 (s, 2H), 3.77 (s, 3H), 3.69 (s, 3H), 1.59 (t, $J=4.4$ Hz, 2H), 1.25 (t, $J=4.4$ Hz, 2H).

Step 3: (1-(2-((4-methoxybenzyl)oxy)phenoxy)cyclopropyl)methanol

5




To a stirred solution of methyl 1-(2-((4-methoxybenzyl)oxy)phenoxy)cyclopropanecarboxylate (Step-2, 2.4 gm, 7.31 mmol) in THF (50 ml) was added LAH (0.41 gm, 10.97 mmol) at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 3 hr. The completion of reaction was monitored by TLC. Excess of reagent was quenched with saturated NH_4Cl solution (10 ml) at 0°C . Reaction mixture was filtered through bed of Na_2SO_4 ; washed with ethyl acetate (2 x 50 ml). Filtrate was dried over anhydrous sodium sulphate and concentrated under reduced pressure to get a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 35% ethyl acetate in hexanes as an eluent to yield the title compound (2.0 g, 91.3%)

MS: m/z 323 (M+23),

^1H NMR (CDCl_3 , 400 MHz): δ 7.36 (d, $J=8.4$ Hz, 2H), 7.13 (d, $J=7.6$ Hz, 1H), 6.88-6.97 (m, 5H), 5.04 (s, 2H), 3.80 (s, 3H), 3.66 (d, $J=6.0$ Hz, 2H), 2.60 (t-exchanges with D_2O , $J=6.0$ Hz, 1H), 1.14 (t, $J=6.4$ Hz, 2H), 0.79 (t, $J=6.4$ Hz, 2H).

Step 4: 2-(1-(hydroxymethyl)cyclopropoxy)phenol




To a stirred solution of 10% palladium on carbon (1.5 gm) in methanol (25 ml), was added solution of 1-(2-((4-methoxybenzyl)oxy)phenoxy)cyclopropyl)methanol (Step-3, 1.5 gm, 5.00 mmol) in methanol (25 ml). To this mixture ammonium formate
 5 (12.60 gm, 200.00 mmol) was added at 25°C under nitrogen atmosphere. The resulting mixture was stirred at 60°C for 3 hr. The completion of reaction was monitored by TLC. Reaction mixture was cooled to room temperature and filtered through bed of celite; washed with DCM (2 x 50 ml). Filtrate was concentrated under reduced pressure to get a crude product; which was purified by again it
 10 dissolved in DCM (100 ml) and resulting solid was filtered. Filtrate was concentrated under reduced pressure to yield the title compound (0.85 g, 94.4%)

MS: m/z 203 (M+23),

^1H NMR (CDCl_3 , 400 MHz): δ 7.02 (d, $J=8.4$ Hz, 1H), 6.89-6.93 (m, 2H), 6.76-6.81 (m, 1H), 3.78 (s, 2H), 2.30 (bs-exchanges with D_2O , 2H), 1.08 (t, $J=6.4$ Hz, 2H),
 15 0.82 (t, $J=6.4$ Hz, 2H).

Step 5: 3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropane]




To a stirred solution of 2-(1-(hydroxymethyl)cyclopropoxy)phenol (Step-4, 1.2 gm ,
 20 6.66 mmol) in DCM (30 ml.) was added triphenyl phosphine (1.92 gm, 7.32 mmol) at 0°C followed by addition of diethyl azodicarboxylate (1.39 gm, 1.26 ml, 7.99 mmol) under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was diluted with DCM (50 ml), washed with water (2x 20 ml) followed by brine (20 ml).

Combined organic layer was dried over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 10% ethyl acetate in hexanes as an eluent to yield the title compound (0.91 g, 84.2%)

5 MS: m/z No Ionization,

^1H NMR (CDCl_3 , 400 MHz): δ 6.78-6.93 (m, 4H), 4.14 (s, 2H), 1.09 (t, $J=6.4$ Hz, 2H), 0.79 (t, $J=6.4$ Hz, 2H).


Step 6: mixture of 2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)ethanone



10

And

2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)ethanone




15

To a stirred solution of AlCl_3 (0.88 gm, 6.66 mmol) in CS_2 (5 ml) was added solution of 3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropane] (Step-5, 0.9 gm, 5.55 mmol) in CS_2 (5 ml) and 2-bromoacetyl bromide (1.35 gm, 0.58 ml, 6.66 mmol) in a drop wise manner at 0°C . The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was quenched by addition of cold water (10 ml). Aqueous layer was extracted with DCM (2 x 50 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 20% ethyl

20


acetate in hexanes as an eluent to yield mixture of 2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)ethanone and 2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)ethanone (0.4 gm, 25.47%)

Step 7: Mixture 3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)hexane-1,4-dione



And


3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)hexane-1,4-dione



To the stirred solution of pulverized sodium (0.034 gm, 1.47 mmol) in toluene (5 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.15 gm, 1.36 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of mixture of 2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)ethanone and 2-bromo-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)ethanone (step 6, 0.35 gm, 1.23 mmol) in toluene (5 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (5 ml) and extracted with ethyl acetate (2x 30 ml) and the combined organic layer was dried

over anhydrous Na_2SO_4 . The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 25% ethyl acetate in hexanes as an eluent to yield mixture of 3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)hexane-1,4-dione and 3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)hexane-1,4-dione (0.23 gm, 58.9%).


Step 8: 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide



10

And

4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide




15

To the solution of the mixture of 3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)hexane-1,4-dione and 3-acetyl-1-(3H-spiro[benzo[b][1,4]dioxine-

2,1'-cyclopropan]-6-yl)hexane-1,4-dione (step 7, 0.2 gm, 0.63 mmol) in toluene:acetic acid (5:0.5 ml) was added 4-aminobenzenesulfonamide (0.13 gm, 0.75 mmol) at room temperature under nitrogen atmosphere. To this reaction mixture *p*-toluene sulphonic acid (0.015 gm, 0.09 mmol) was added and heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (10 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (50 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 40 % ethyl acetate in hexanes as an eluent to yield mixture of the 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide and 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide. The mixture was separated by preparative HPLC to yield the first title compound (0.035 gm, 12.2%) and second title compound (0.05 gm, 17.48%).


First title compound: 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide



MS: *m/z* 453 (M+1),

^1H NMR (DMSO, 400 MHz): δ 7.88 (d, $J=8.4$ Hz, 2H), 7.52 (bs-exchanges with D_2O , 2H), 7.44 (d, $J=8.4$ Hz, 2H), 6.80 (s, 1H), 6.72 (d, $J=8.4$ Hz, 1H), 6.55 (d, $J=2.0$ Hz, 1H), 6.47 (dd, $J=8.4$, 2.0 Hz, 1H), 4.14 (s, 2H), 2.81 (q, $J=7.2$ Hz, 2H), 2.29 (s, 3H), 1.05 (t, $J=7.2$ Hz, 3H), 0.94 (t, $J=5.6$ Hz, 2H), 0.80 (t, $J=5.6$ Hz, 2H).

- 5 Second title compound: 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide




MS: m/z 453 ($M+1$),

- 10 ^1H NMR (DMSO, 400 MHz): δ 7.89 (d, $J=8.4$ Hz, 2H), 7.53 (bs-exchanges with D_2O , 2H), 7.47 (d, $J=8.4$ Hz, 2H), 6.82 (s, 1H), 6.70 (d, $J=2.0$ Hz, 1H), 6.61 (d, $J=8.4$ Hz, 1H), 6.42 (dd, $J=8.4$, 2.0 Hz, 1H), 4.13 (s, 2H), 2.82 (q, $J=7.2$ Hz, 2H), 2.29 (s, 3H), 1.06 (t, $J=7.2$ Hz, 3H), 0.96 (t, $J=5.6$ Hz, 2H), 0.85 (t, $J=5.6$ Hz, 2H).

- Example 10: Preparation of 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.**
- 15


69




And

4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

5




Step 1: Mixture of 1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-bromoethanone



And


1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-bromoethanone

10




To a stirred solution of AlCl_3 (1.31 gm, 6.40 mmol) in DCE (30 ml) was added solution of 1-(4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethanone (prepared according to the procedure reported in US 4808597, 1.2 gm, 5.91 mmol) in DCE (10 ml) and 2-bromoacetyl bromide (0.94 gm, 0.41 ml, 7.00 mmol) in a drop wise manner at 0°C . The resulting mixture was stirred at room temperature for 2 hr. The completion of reaction was monitored by TLC. Reaction mixture was poured into cold water (30 ml). Aqueous layer was extracted with DCM (2 x 50 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 30% ethyl acetate in hexanes as an eluent to yield the mixture of 1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-bromoethanone and 1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-bromoethanone (0.80 gm, 42.10%).

Step 2: Mixture of 3-acetyl-1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione




And

3-acetyl-1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione




To the stirred solution of pulverized sodium (0.085 gm, 3.69 mmol) in toluene (10 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.30 gm, 2.71 mmol) at 0°C and
 5 reaction mixture was stirred at room temperature for 2 hr. To this was added solution of mixture of 1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-bromoethanone and 1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-bromoethanone (step 1, 0.80 gm, 2.47 mmol) in toluene (10 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was
 10 monitored by TLC. To this reaction mixture was added cold water (10 ml) and extracted with ethyl acetate (2x 50 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 35% ethyl acetate in hexanes as an eluent to yield mixture of 3-acetyl-1-(1-acetyl-4,4-
 15 dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione and 3-acetyl-1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione (0.60 gm, 54.5%).

Step 3: 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



And

4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




5

To the solution of the mixture of 3-acetyl-1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione and 3-acetyl-1-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione (step 2, 0.25 gm , 0.70 mmol) in acetic acid (5 ml) was added 4-aminobenzenesulfonamide (0.24 gm, 1.40 mmol) at room temperature. Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (10 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (50 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 50 % ethyl acetate in hexanes as an eluent to yield mixture of the 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-

tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide and 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide. The mixture was separated by preparative HPLC to yield the first title compound (0.045 gm, 13.0%) and second title compound (0.030 gm, 8.69%).


First title compound: 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 494 ($M+1$),

^1H NMR (DMSO, 400 MHz): δ 7.90 (d, $J=8.4$ Hz, 2H), 7.47-7.53 (m, 5H), 7.05 (d, $J=8.0$ Hz, 1H), 6.94 (s, 1H), 6.75 (s, 1H), 3.62 (t, $J=5.6$ Hz, 2H), 2.85 (q, $J=7.2$ Hz, 2H), 2.34 (s, 3H), 2.08 (s, 3H), 1.60 (t, $J=5.6$ Hz, 2H), 1.08 (t, $J=7.2$ Hz, 3H), 0.92 (s, 6H).


Second title compound: 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 494 ($M+1$),

^1H NMR (DMSO, 400 MHz): δ 7.89 (d, $J=8.4$ Hz, 2H), 7.48-7.54 (m, 4H), 7.29 (d, $J=8.0$ Hz, 1H), 6.86-6.94 (m, 3H), 3.63 (t, $J=6.0$ Hz, 2H), 2.85 (q, $J=7.2$ Hz, 2H), 2.50 (s, 3H), 2.30 (s, 3H), 1.65 (t, $J=6.0$ Hz, 2H), 1.18 (s, 6H), 1.06 (t, $J=7.2$ Hz, 3H).


Example 11: Preparation of 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.



10

And


4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.



To the stirred solution of mixture of the 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide and 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (step 3 in Example-8, 0.1 gm, 0.20 mmol) in acetonitrile (5 ml) was 6M HCl (10 ml) at room temperature. Reaction mixture was heated at 100° C for 4 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (20 ml) and stirred for 10 minutes.

Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (30 ml) was added to the residue, washed with water (10 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 55% ethyl acetate in hexanes as an eluent to yield the first title compound (0.035 gm, 38.46%) and second title compound (0.025 gm, 27.47%).


First title compound: 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



MS: m/z 452 ($M+1$),

^1H NMR (CDCl_3 , 400 MHz): δ 7.96 (d, $J=8.4$ Hz, 2H), 7.28 (d, $J=8.4$ Hz, 2H), 6.79 (dd, $J=8.0$, 2.0 Hz, 1H), 6.60 (s, 1H), 6.58 (d, $J=2.0$ Hz, 1H), 6.31 (d, $J=8.0$ Hz, 1H), 4.87 (bs-exchanges with D_2O , 2H), 3.24 (t, $J=5.6$ Hz, 2H), 2.85 (q, $J=7.2$ Hz, 2H), 2.44 (s, 3H), 1.62 (t, $J=5.6$ Hz, 2H), 1.59 (bs-exchanges with D_2O , 1H), 1.21 (t, $J=7.2$ Hz, 3H), 0.98 (s, 6H).

Second title compound: 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




10 MS: m/z 452 ($M+1$),

^1H NMR (CDCl_3 , 400 MHz): δ 7.95 (d, $J=8.4$ Hz, 2H), 7.29 (d, $J=8.4$ Hz, 2H), 6.93 (d, $J=8.0$ Hz, 1H), 6.65 (s, 1H), 6.19 (d, $J=2.0$ Hz, 1H), 6.16 (dd, $J=8.0$, 2.0 Hz, 1H), 4.99 (bs-exchanges with D_2O , 2H), 3.25 (t, $J=5.6$ Hz, 2H), 2.84 (q, $J=7.2$ Hz, 2H), 2.40 (s, 3H), 1.68 (t, $J=5.6$ Hz, 2H), 1.66 (bs-exchanges with D_2O , 1H), 1.22 (s, 6H), 1.20 (t, $J=7.2$ Hz, 3H).


Example 12: Preparation of 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.

77




And

4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide.




5

Step 1: Mixture of 6-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one



And


7-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one



10


To a stirred solution of AlCl_3 (7.50 gm, 56.25 mmol) in CS_2 (30 ml) was added solution of 4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one (prepared according to the procedure reported in US 4808597, 2.5 gm, 14.20 mmol) in CS_2 (20 ml) and 2-bromoacetyl bromide (4.32 gm, 1.88 ml, 21.70 mmol) in a drop wise manner at 0°C. The resulting mixture was stirred at reflux temperature for 3 hr. The completion of reaction was monitored by TLC. Reaction mixture was poured into cold 2N HCl (30 ml). Aqueous layer was extracted with ethyl acetate (2 x 100 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 35% ethyl acetate in hexanes as an eluent to yield the mixture of 6-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one and 7-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one (2.00 gm, 47.4%).

Step 2: Mixture of 3-acetyl-1-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione




And

3-acetyl-1-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione




To the stirred solution of pulverized sodium (0.184 gm, 8.00 mmol) in toluene (15 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.77 gm, 6.70 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added
 5 solution of mixture of 6-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one and 7-(2-bromoacetyl)-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one (step 1, 2.00 gm, 6.70 mmol) in toluene (15 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (20 ml) and extracted with ethyl acetate (2x
 10 100 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 35% ethyl acetate in hexanes as an eluent to yield mixture of 3-acetyl-1-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione and 3-acetyl-1-(4,4-dimethyl-2-oxo-
 15 1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione (1.30 gm, 58.55%).

Step 3: 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




And

20 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide



- To the solution of the mixture of 3-acetyl-1-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione and 3-acetyl-1-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)hexane-1,4-dione (step 2, 1.30 gm, 3.95 mmol) in acetic acid (20 ml) was added 4-aminobenzenesulfonamide (1.35 gm, 7.90 mmol) at room temperature. Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (30 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (100 ml) was added to the residue, washed with water (30 ml). Combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography over silica gel (100-200 mesh) using 50 % ethyl acetate in hexanes as an eluent to yield mixture of the 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide and 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (0.6 gm, 32.78%). 0.150 gm of the mixture was separated by preparative HPLC to yield the first title compound (0.035 gm, 23.33%) and second title compound (0.025 gm, 16.66%).
- First title compound: 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide


81



MS: m/z 466 ($M+1$),

^1H NMR (DMSO, 400 MHz): δ 10.46 (bs-exchanges with D_2O , 1H), 7.99 (d, $J=8.4$ Hz, 2H), 7.56-7.72 (m, 6H), 6.97 (d, $J=8.4$ Hz, 1H), 6.21 (s, 1H), 2.44 (s, 2H), 2.30 (q, $J=7.2$ Hz, 2H), 2.21 (s, 3H), 1.27 (s, 6H), 1.01 (t, $J=7.2$ Hz, 3H).

Second title compound: 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide




10

MS: m/z 466 ($M+1$),


^1H NMR (DMSO, 400 MHz): δ 10.13 (bs-exchanges with D_2O , 1H), 7.89 (d, $J=8.4$ Hz, 2H), 7.46-7.51 (m, 4H), 7.03 (dd, $J=8.0, 2.0$ Hz, 1H), 6.87 (s, 1H), 6.71-6.74 (m, 2H), 2.83 (q, $J=7.2$ Hz, 2H), 2.33 (s, 3H), 2.21 (s, 2H), 1.07 (t, $J=7.2$ Hz, 3H), 0.94 (s, 6H).

15

Example 13: Preparation of 4-(2-methyl-3-propionyl-5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide.



Step 1: 6-(2-bromoacetyl)-1,4,4-trimethyl-3,4-dihydroquinolin-2(1H)-one




5

To a stirred solution of AlCl_3 (2.36 gm, 17.7 mmol) in CS_2 (30 ml) was added solution of 1,4,4-trimethyl-3,4-dihydroquinolin-2(1H)-one, (prepared according to the procedure reported in European Journal of Medicinal Chemistry, 2008, 43, 8, 1730 - 1736, 2.8 gm, 14.80 mmol) in CS_2 (20 ml) and 2-bromoacetyl bromide (3.26 gm, 1.42 ml, 16.20 mmol) in a drop wise manner at 0°C . The resulting mixture was stirred at reflux temperature for 4 hr. The completion of reaction was monitored by TLC. Reaction mixture was poured into cold water (50 ml). Aqueous layer was extracted with ethyl acetate (2 x 100 ml). Organic layers separated were dried over anhydrous sodium sulphate, filtered and concentrated at reduced pressure to get a crude product; which was purified by column chromatography using 45% ethyl acetate in hexanes as an eluent to yield the title compound (2.00 gm, 43.57%).

MS: m/z 311 ($\text{M}+1$),


Step 2: 3-acetyl-1-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione



To the stirred solution of pulverized sodium (0.220 gm, 9.56 mmol) in toluene (15 ml) was added hexane-2,4-dione (prepared according to the procedure given in J. Amer. Chem. Soc., 1945, 67, 9, , 1510-1512, 0.87 gm, 7.60 mmol) at 0°C and reaction mixture was stirred at room temperature for 2 hr. To this was added solution of 6-(2-bromoacetyl)-1,4,4-trimethyl-3,4-dihydroquinolin-2(1H)-one (step 1, 2.00 gm, 6.40 mmol) in toluene (15 ml) and reaction mixture was heated at 60°C for 2 hr under stirring. The completion of reaction was monitored by TLC. To this reaction mixture was added cold water (20 ml) and extracted with ethyl acetate (2x 100 ml) and the combined organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by column chromatography using 35% ethyl acetate in hexanes as an eluent to yield title compound (0.72 gm, 32.57%).

MS: *m/z* 344 (M+1),

Step 3: 4-(2-methyl-3-propionyl-5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide



To the solution of the 3-acetyl-1-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)hexane-1,4-dione (step 2, 0.70 gm, 2.04 mmol) in acetic acid (15 ml) was added 4-aminobenzenesulfonamide (0.70 gm, 4.08 mmol) at room temperature.

- 5 Reaction mixture was heated at 110° C for 3 hr. The completion of reaction was monitored by TLC. Solvent was evaporated at reduced pressure. Residue so obtained was taken in solution of ammonia in chloroform (30 ml) and stirred for 10 minutes. Reaction mixture was again concentrated at reduced pressure. Ethyl acetate (100 ml) was added to the residue, washed with water (30 ml). Combined
10 organic layer was dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure to obtain a crude product; which was purified by preparative HPLC to yield the title compound (0.110 gm, 11.2%).

MS: *m/z* 480 (M+1),

- ¹HNMR (CDCl₃, 400 MHz): δ 7.99 (d, *J*=8.4 Hz, 2H), 7.32 (d, *J*=8.4 Hz, 2H), 7.03
15 (dd, *J*=8.4, 2.0 Hz, 1H), 6.84 (d, *J*=8.4 Hz, 1H), 6.77 (d, *J*=2.0 Hz, 1H), 6.73 (s, 1H), 4.98 (bs-exchanges with D₂O, 2H), 3.33 (s, 3H), 2.89 (q, *J*=7.2 Hz, 2H), 2.46 (s, 3H), 2.41 (s, 2H), 1.22 (t, *J*=7.2 Hz, 3H), 1.07 (s, 6H).

Example 14: Pharmacological screening

- Compounds were tested in a cell-based real-time kinetic assay in human IMR-32
20 cells with native expression of α7nAChR. The increase in intracellular Ca²⁺ levels was measured in a Fluorometric Imaging Plate Reader (FLIPR). Test compound and agonist solutions were made in assay buffer (HBSS, pH 7.4, 20 mM HEPES, and 10 mM CaCl₂). Briefly, cells were plated into Poly-D-Lysine coated back-walled clear-


bottom 96-well microplates at a density of 80,000 to 100,000 cells/well and incubated at 37°C/5% CO₂ for 40-48 h prior to the experiment. For evaluation of compound mediated potentiation of agonist response, growth media was removed from the wells and 200 µl of FLIPR calcium 4 dye (Molecular Devices), reconstituted in assay buffer, and was added to the wells. After dye loading, microplates were incubated for 30 min at 37°C and 30 min at room temperature and then directly transferred to the FLIPR. Baseline fluorescence was monitored for the first 10 to 30 s followed by the addition of 25 µl of test compound solution and subsequent monitoring of fluorescence changes for up to 10 min. This was followed by addition of 25 µl of agonist (PNU-282987, 10 µM) solution and measurement of fluorescence for 4 min. (Faghih R. et al. 2009, *J. Med. Chem.* **52**, 3377 – 84.)

The compound induced fold increase in agonist response (fold PAM activity) was computed by dividing the maximum effect (Max-Min fluorescence) obtained with test compound in presence of agonist with the agonist-alone effect. EC₅₀ of the compound was calculated using GraphPad Prism software version 5.0, by plotting compound concentrations against fold PAM activity.

The compounds of the present invention showed 2 to 30 fold activation at 1 µM concentration.

CLAIMS

1. A compound of the general formula I, its tautomeric forms, its stereoisomers and its
5 pharmaceutically acceptable salts;




wherein,

- R^1 is selected from hydrogen, halogen, optionally substituted alkyl, perhaloalkyl,
optionally substituted cycloalkyl, optionally substituted aryl; optionally substituted
10 heterocyclyl, optionally substituted heteroaryl;

R^2 is selected from optionally substituted alkyl, optionally substituted heteroalkyl,
optionally substituted aryl, optionally substituted heteroaryl, optionally substituted
cycloalkyl, optionally substituted heterocyclyl, or $-NR^5(R^6)$, $-A^1R^5$, $-N(R^5)OR^6$;

- R^3 is selected from hydrogen, optionally substituted alkyl, halo, optionally substituted
15 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally
substituted heteroaryl, cyano, nitro or $-NR^5(R^6)$, $-OR^5$;

R^4 is



wherein, phenyl ring 'D' is fused with ring 'E', which is a non-aromatic five to eight member ring inclusive of 'Y' group(s);

Y is independently selected at each repetition from -O-, -S-, -NH-, , or ,

where q = 1 - 4; wherein when Y is selected as -NH- or , it is optionally substituted by $[R^8]_n$;

wherein, R^5 and R^6 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $R^{9a}C(=A^1)-$;

10 R^7 is selected independently at each occurrence from the group consisting of halogen, optionally substituted alkyl, optionally substituted cycloalkyl;

R^8 is independently selected at each occurrence from the group consisting of optionally substituted alkyl, R^9A^1- , $R^{9a}C(=A^1)-$;

m = 0 to 2;

15 n = 0 to 3;

p = 0 to 4;

such that, when p = 0 then n $\neq$ 0;

20 wherein, R^9 wherever it appears, is selected from hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; and A^1 is selected from O and S;

R^{9a} wherever it appears, is selected from optionally substituted C_{1-6} alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

wherein,

5 "optionally substituted alkyl", means a alkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, heteroaryl, cycloalkyl, $R^{10a}SO_2-$, $R^{10}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;

10 "optionally substituted heteroalkyl" means a heteroalkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, heteroaryl, cycloalkyl.

"optionally substituted cycloalkyl" means a cycloalkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, heteroaryl, alkyl, $R^{10a}C(=O)-$, $R^{10a}SO_2-$, $R^{10}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;

15

"optionally substituted aryl" means (i) an aryl group optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, C_3 to C_6 cycloalkyl, C_1 to C_6 perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N- , alkyl-SO₂-, perhaloalkyl-SO₂-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, $H_2NC(=O)-$, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H_2NSO_2- , 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-, (ii) an aryl ring optionally fused with

20

25

cycloalkane or heterocycle across a bond optionally substituted with oxo, alkyl or alkyl-C(=O)-;


“optionally substituted heterocyclyl” means a (i) heterocyclyl group optionally substituted on ring carbons with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, heteroaryl, alkyl, $R^{10}A^1$ -, $R^{10a}OC(=O)$ -, $R^{10a}C(=O)O$ -, $(R^{10})(H)NC(=O)$ -, $(R^{10})(alkyl)NC(O)$ -, $R^{10a}C(=O)N(H)$ -, $(R^{10})(H)N$ -, $(R^{10})(alkyl)N$ -, $(R^{10})(H)NC(=A^1)N(H)$ -, $(R^{10})(alkyl)NC(=A^1)N(H)$ -; (ii) heterocyclyl group optionally substituted on ring nitrogen(s) with substituents selected from the group consisting of aryl, heteroaryl, alkyl, $R^{10a}C(=O)$ -, $R^{10a}SO_2$ -, $R^{10a}OC(=O)$ -, $(R^{10})(H)NC(=O)$ -, $(R^{10})(alkyl)NC(=O)$ -;

“optionally substituted heteroaryl” means a heteroaryl group optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, C_3 to C_6 cycloalkyl, C_1 to C_6 perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N -, alkyl-SO₂-, perhaloalkyl-SO₂-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, $H_2NC(=O)$ -, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H_2NSO_2 -, 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-;


wherein R^{10} is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and A^1 is selected from S and O; and R^{10a} is selected from alkyl, perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl.

2. The compound of formula I as claimed in claim 1, wherein R^1 is selected as methyl.
3. The compound of formula I as claimed in claim 1, wherein R^2 is selected from ethyl and ethoxy.
- 25 4. The compound of formula I as claimed in claim 1, wherein R^3 is selected from hydrogen and methyl.

5. The compound of formula I as claimed in claim 1, wherein R^4 is selected from



6. The compound of formula I as claimed in claim 1, wherein R^1 is selected from methyl, R^2 is selected from ethyl and ethoxy, R^3 is selected from hydrogen and methyl, and R^4 is selected from



5

7. The compound of formula I as claimed in claim 1, wherein the compound is selected from-

4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

10

4-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

15

4-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5-dimethyl-4-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

Ethyl 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,4-dimethyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylate;

5 4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

10 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

15 4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

20 4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide;

4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide;

25 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

30 4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;


4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

5 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

10 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(2-methyl-3-propionyl-5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

- 15 **8.** A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 9.** Use of compound of claim 1 for the manufacture of a medicament for preventing or treating a disease or its symptoms or a disorder mediated partially or completely by
- 20 nicotinic acetylcholine receptors.
- 10.** Use of compound of formula (I), its tautomeric forms, its stereoisomers, and its pharmaceutically acceptable salts,




wherein,

R^1 is selected from hydrogen, halogen, optionally substituted alkyl, perhaloalkyl, optionally substituted cycloalkyl, optionally substituted aryl; optionally substituted heterocyclyl, optionally substituted heteroaryl;

R^2 is selected from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or $-NR^5(R^6)$, $-A^1R^5$, $-N(R^5)OR^6$;

R^3 is selected from hydrogen, optionally substituted alkyl, halo, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, cyano, nitro or $-NR^5(R^6)$, $-OR^5$;

R^4 is



wherein, phenyl ring 'D' is fused with ring 'E', which is a non-aromatic five to eight member ring inclusive of 'Y' group(s);

Y is independently selected at each repetition from -O-, -S-, -NH-, , or ,

where $q = 1 - 4$; wherein when Y is selected as -NH- or , it is optionally substituted by $[R^8]_n$;

5 wherein, R^5 and R^6 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $R^{9a}C(=A^1)-$;

R^7 is selected independently at each occurrence from the group consisting of halogen, optionally substituted alkyl, optionally substituted cycloalkyl;

10 R^8 is independently selected at each occurrence from the group consisting of optionally substituted alkyl, R^9A^1- , $R^{9a}C(=A^1)-$;

$m = 0$ to 2 ;

$n = 0$ to 3 ;

$p = 0$ to 4 ;

15 wherein, R^9 wherever it appears, is selected from hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; and A^1 is selected from O and S;

20 R^{9a} wherever it appears, is selected from optionally substituted C_{1-6} alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

wherein,

"optionally substituted alkyl", means a alkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl, $R^{10a}SO_2-$, $R^{10}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;

"optionally substituted heteroalkyl" means a heteroalkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, hereroaryl, cycloalkyl.

"optionally substituted cycloalkyl" means a cycloalkyl group optionally substituted with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, hereroaryl, alkyl, $R^{10a}C(=O)-$, $R^{10a}SO_2-$, $R^{10}A^1-$, $R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$, $R^{10a}C(=O)N(H)-$, $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$;

"optionally substituted aryl" means (i) an aryl group optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, C_3 to C_6 cycloalkyl, C_1 to C_6 perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N- , alkyl- SO_2- , perhaloalkyl- SO_2- , alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, $H_2NC(=O)-$, alkyl-N(alkyl) SO_2- , alkyl-N(H) SO_2- , H_2NSO_2- , 3 to 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S optionally substituted with alkyl or alkyl-C(=O)-, (ii) an aryl ring optionally fused with cycloalkane or heterocycle across a bond optionally substituted with oxo, alkyl or alkyl-C(=O)-;

"optionally substituted heterocyclyl" means a (i) heterocyclyl group optionally substituted on ring carbons with 1 to 6 substituents selected independently from the group consisting of oxo, halogen, nitro, cyano, aryl, hereroaryl, alkyl, $R^{10}A^1-$,

$R^{10a}OC(=O)-$, $R^{10a}C(=O)O-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(O)-$, $R^{10a}C(=O)N(H)-$,
 $(R^{10})(H)N-$, $(R^{10})(alkyl)N-$, $(R^{10})(H)NC(=A^1)N(H)-$, $(R^{10})(alkyl)NC(=A^1)N(H)-$; (ii)
 heterocyclyl group optionally substituted on ring nitrogen(s) with substituents
 selected from the group consisting of aryl, heteroaryl, alkyl, $R^{10a}C(=O)-$, $R^{10a}SO_2-$,
 5 $R^{10a}OC(=O)-$, $(R^{10})(H)NC(=O)-$, $(R^{10})(alkyl)NC(=O)-$;

"optionally substituted heteroaryl" means a heteroaryl group optionally substituted
 with 1 to 3 substituents selected independently from the group consisting of halogen,
 nitro, cyano, hydroxy, C_1 to C_6 alkyl, C_3 to C_6 cycloalkyl, C_1 to C_6 perhaloalkyl,
 alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N- , alkyl-SO₂-,
 10 perhaloalkyl-SO₂-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-,
 alkyl-N(H)C(=O)-, $H_2NC(=O)-$, alkyl-N(alkyl)SO₂-, alkyl-N(H)SO₂-, H_2NSO_2- , 3 to
 6 membered heterocycle containing 1 to 2 heteroatoms selected from N, O and S
 optionally substituted with alkyl or alkyl-C(=O)-;

15 wherein R^{10} is selected from hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or
 heterocyclyl; and A^1 is selected from S and O; and R^{10a} is selected from alkyl,
 perhaloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl,
 for the manufacture of a medicament for treating a disease, disorder, or condition
 mediated partially or completely by nicotinic acetylcholine receptor.

20

11. Use of compound of claim 10, wherein the compounds are selected from,

4-(5-(4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

25

4-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3,5-dimethyl-4-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

Ethyl 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,4-dimethyl-1-(4-sulfamoylphenyl)-1H-pyrrole-3-carboxylate;

5 4-(5-(2,3-dihydro-1H-inden-4-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(2,2-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

10

4-(5-(8-fluoro-4,4-dimethylchroman-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

15

4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

20

4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-7-yl)-1H-pyrrol-1-yl)benzenesulfonamide;

25

4-(2-methyl-3-propionyl-5-(3H-spiro[benzo[b][1,4]dioxine-2,1'-cyclopropan]-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide;

30

4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(1-acetyl-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

5 4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(4,4-dimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

10 4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

4-(5-(4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide;

15 4-(2-methyl-3-propionyl-5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-1H-pyrrol-1-yl)benzenesulfonamide;

20 4-(2-methyl-3-propionyl-5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrol-1-yl)benzenesulfonamide.

12. Use of compound of claim 10, wherein the disorder or condition or disease is selected from the group comprising of Alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of Parkinson's disease, attention deficit disorder, attention deficit hyperactivity disorder, dementia associated with Lewy bodies, AIDS dementia complex, Pick's disease, dementia associated with Down's syndrome, Huntington's disease, cognitive deficits associated with traumatic brain injury, cognitive and sensorimotor gating deficits associated with schizophrenia, cognitive deficits associated with bipolar disorder, cognitive impairments associated with depression, acute pain, post-surgical or post-operative pain, chronic pain, inflammation, inflammatory pain, neuropathic pain, smoking cessation, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated

with vascularization of skin grafts, and lack of circulation, arthritis, rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, pouchitis, inflammatory bowel disease, celiac disease, periodontitis, sarcoidosis, pancreatitis, organ transplant rejection, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, septic shock, toxic shock syndrome, sepsis syndrome, depression, and rheumatoid spondylitis, comprising the step of administering a compound of formula I.

13. Use of compound of claim 10, wherein the disease or disorder or condition is selected from the group classified or diagnosed as major or minor neurocognitive disorders, or disorders arising due to neurodegeneration.

14. Use of compound of claim 10, comprising administering a compound of formula I in combination with or as adjunct to medications used in the treatment of attention deficit hyperactivity disorders, schizophrenia, and other cognitive disorders such as Alzheimer's disease, Parkinson's dementia, vascular dementia or dementia associated with Lewy bodies, traumatic brain injury.

15. Use of compound of claim 10, further comprising administering a compound of formula I in combination with or as an adjunct to acetylcholinesterase inhibitors, disease modifying drugs or biologics for neurodegenerative disorders, dopaminergic drugs, antidepressants, typical or an atypical antipsychotic.

16. Use of compound of claim 1 for the manufacture of a medicament for preventing or treating a disease or its symptoms or a disorder mediated partially or completely by nicotinic acetylcholine receptors, comprising administration of therapeutically effective amount of a compound of claim 1 to a subject having or susceptible to said disease or its symptoms or disorder.